<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomol Struct Dyn</journal-id><journal-id journal-id-type="iso-abbrev">J Biomol Struct Dyn</journal-id><journal-title-group><journal-title>Journal of Biomolecular Structure &#x00026; Dynamics</journal-title></journal-title-group><issn pub-type="ppub">0739-1102</issn><issn pub-type="epub">1538-0254</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7738211</article-id><article-id pub-id-type="pmid">33297848</article-id><article-id pub-id-type="doi">10.1080/07391102.2020.1850358</article-id><article-id pub-id-type="publisher-id">1850358</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>In vitro</italic> antimicrobial, physicochemical, pharmacokinetics and molecular docking studies of benzoyl uridine esters against SARS-CoV-2 main protease</article-title><alt-title alt-title-type="left-running-head">M. M. Matin et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Biomolecular Structure and Dynamics</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4965-2280</contrib-id><name><surname>Matin</surname><given-names>Mohammed Mahbubul</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6887-9344</contrib-id><name><surname>Uzzaman</surname><given-names>Monir</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Chowdhury</surname><given-names>Shagir Ahammad</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Bhuiyan</surname><given-names>Md. Mosharef Hossain</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><aff id="AF0001"><label>a</label><institution>Bioorganic and Medicinal Chemistry Laboratory, Department of Chemistry, Faculty of Science, University of Chittagong</institution>, <city>Chattogram</city>, <country>Bangladesh</country></aff><aff id="AF0002"><label>b</label><institution>Faculty of Engineering, Department of Applied Chemistry and Biochemical Engineering, Shizuoka University</institution>, <city>Hamamatsu</city>, <country>Japan</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Mohammed Mahbubul Matin <email>mahbubchem@cu.ac.bd</email><institution>Bioorganic and Medicinal Chemistry Laboratory, Department of Chemistry, Faculty of Science, University of Chittagong</institution>, <city>Chattogram</city><postal-code>4331</postal-code>, <country>Bangladesh</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>12</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>13</lpage><permissions><copyright-statement>&#x000a9; 2020 Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TBSD_0_1850358.pdf"/><abstract><title>Abstract</title><p>Different esters were found potential against microorganisms, and could be a better choice to solve the multidrug resistant (MDR) pathogenic global issue due to their improved biological and pharmacokinetic properties. In this view, several 4-<italic>t</italic>-butylbenzoyl uridine esters <bold>4&#x02013;15</bold> with different aliphatic and aromatic groups were synthesized for antimicrobial, physicochemical and biological studies. <italic>In vitro</italic> antimicrobial tests against nine bacteria and three fungi along with prediction of activity spectra for substances (PASS) indicated promising antifungal functionality of these uridine esters compared to the antibacterial activities. In support of this observation their cytotoxicity and molecular docking studies have been performed against lanosterol 14&#x003b1;-demethylase (CYP51A1) and <italic>Aspergillus flavus</italic> (1R51). Significant binding affinities were observed against SARS-CoV-2 main protease (7BQY) considering hydroxychloroquine (HCQ) as standard. ADMET predictions were investigated to evaluate their absorption, metabolism and toxic properties. Most of the uridine esters showed better results than that of the HCQ. Overall, the present study might be useful for the development of uridine-based novel MDR antimicrobial and COVID-19 drugs.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="TBSD_A_1850358_UF0001_C"/></fig><p>Communicated by Ramaswamy H. Sarma</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Uridine esters</kwd><kwd>density functional theory</kwd><kwd>thermodynamic and orbital properties</kwd><kwd>antimicrobial activities</kwd><kwd>PASS and ADMET predications</kwd><kwd>SARS-CoV-2 main protease</kwd></kwd-group><counts><fig-count count="10"/><table-count count="10"/><page-count count="13"/><word-count count="8240"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Uridine (<bold>1</bold>), a natural and necessary nucleoside, is one of the four basic components of ribonucleic acid (RNA). It is a structural element of many bioactive compounds, and it has crucial role in the pyrimidine metabolism of the brain. Uridine and its nucleotide derivatives may also have an additional role in the function of the central nervous system as signaling molecules (Dobolyi et al., <xref rid="CIT0008" ref-type="bibr">2011</xref>). It has anti depression activity, asthmatic airway inflammation, hepatocyte proliferation (Carlezon et al., <xref rid="CIT0003" ref-type="bibr">2005</xref>). Uridine has sleep-promoting and anti-epileptic effects, might affect mood, improves memory function and influences neuronal plasticity (Siegel et al., 2017). Uridine, sometimes, has been recognized as playing a role in preserving and enhancing hepatic mitochondrial function in the face of challenge by certain liver toxins (Banasch et al., <xref rid="CIT0002" ref-type="bibr">2006</xref>). In addition, uridine (<bold>1</bold>) and some of its biological derivatives behave as antimetabolites, when their extracellular concentrations are higher than those physiological levels (Strasser et al., 2006; Yamamoto et al., <xref rid="CIT0046" ref-type="bibr">2011</xref>).</p><p>Many advantageous findings were reported for the uridine derivatives especially its esters. For example, uridine 5&#x02032; esters showed neuroprotective effect and is capable of compensating the harmful effect of neurotoxins with the increase the 5-HT and 5-HIAA levels (Susilo, 2008). 3&#x02032;,4&#x02032;-Uridine acetonide (<bold>2</bold>, <xref ref-type="fig" rid="F0001">Figure 1</xref>) showed a differential effect and a higher activity over cell viability on MCF-7 human cancer breast cell line than for the CHO-K1 cell line (Escober et al., <xref rid="CIT0010" ref-type="bibr">2016</xref>). Some uridine esters were found to exhibit promising antimicrobial properties (Kabir, Matin, &#x00026; Kawsar, <xref rid="CIT0015" ref-type="bibr">1998</xref>; Kabir, Matin, Kawsar, &#x00026; Anwar, <xref rid="CIT0016" ref-type="bibr">1998</xref>; Kabir, Matin, Mridha, et al., <xref rid="CIT0017" ref-type="bibr">1998</xref>; Kabir et al., <xref rid="CIT0018" ref-type="bibr">1998a</xref>, <xref rid="CIT0015" ref-type="bibr">1998</xref>b) such as 3&#x02032;-<italic>O</italic>-decanoyl-2&#x02032;,5&#x02032;-di-<italic>O</italic>-acetyluridine (<bold>3</bold>) was found very active against <italic>E. coli</italic> (Kabir et al., <xref rid="CIT0013" ref-type="bibr">2002</xref>). Thus, it has been proven that the uridine derivatives especially acyl esters can be used as drugs in order to treat, for instance, Parkinson, Alzheimer, Chorea Huntington or depression with cellular regulatory functions (Escober et al., <xref rid="CIT0010" ref-type="bibr">2016</xref>).</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Structures of <bold>1</bold>&#x02013;<bold>4</bold>.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0001_C"/></fig><p>Although uridine analogues (e.g. doxifluridine) have shown higher activities in the treatment of viral and cancer treatment, their efficiency is sometimes reduced by the appearance of resistance mechanisms (De Clercq, <xref rid="CIT0007" ref-type="bibr">2011</xref>). Hence, search for newer analogues of uridine (nucleoside) got more attention especially esterification of its sugar moiety (Du et al., <xref rid="CIT0009" ref-type="bibr">2018</xref>). However, investigations indicated that selective esterification (acylation) uridine (<bold>1</bold>) creates difficulties due to the presence of one 1&#x000b0; OH group, two 2&#x000b0; OH groups and a NH group. Hence, various methods like direct acylation (Matin, Bhattacharjee, et al., <xref rid="CIT0028" ref-type="bibr">2019</xref>; Matin, Bhuiyan, et al., <xref rid="CIT0032" ref-type="bibr">2019</xref>; Matin, Chakraborty, et al., <xref rid="CIT0033" ref-type="bibr">2020</xref>; Matin, Hasan, et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>; Matin, Roshid, et al., <xref rid="CIT0037" ref-type="bibr">2020</xref>), dibutyltin oxide (DBTO) method (Kabir, Matin, &#x00026; Kawsar, <xref rid="CIT0015" ref-type="bibr">1998</xref>; Kabir, Matin, Kawsar, &#x00026; Anwar, <xref rid="CIT0016" ref-type="bibr">1998</xref>; Kabir, Matin, Mridha, et al., <xref rid="CIT0017" ref-type="bibr">1998</xref>; Kabir et al., <xref rid="CIT0014" ref-type="bibr">1997</xref>, <xref rid="CIT0018" ref-type="bibr">1998a</xref>, <xref rid="CIT0015" ref-type="bibr">1998</xref>b), coupling technique (Steglich esterification) (Clayden et al., <xref rid="CIT0005" ref-type="bibr">2012</xref>), protection&#x02013;deprotection (Matin et al., <xref rid="CIT0029" ref-type="bibr">2017</xref>) and enzymatic method (Du et al., <xref rid="CIT0009" ref-type="bibr">2018</xref>) were reported. Among these methods, direct method generally furnished 5&#x02032;-<italic>O</italic>-substituted esters (Kabir, Matin, &#x00026; Kawsar, <xref rid="CIT0015" ref-type="bibr">1998</xref>; Kabir, Matin, Kawsar, &#x00026; Anwar, <xref rid="CIT0016" ref-type="bibr">1998</xref>; Kabir, Matin, Mridha, et al., <xref rid="CIT0017" ref-type="bibr">1998</xref>; Kabir et al., <xref rid="CIT0014" ref-type="bibr">1997</xref>, <xref rid="CIT0018" ref-type="bibr">1998a</xref>, <xref rid="CIT0015" ref-type="bibr">1998</xref>b) whereas DBTOmethod gave 3&#x02032;-<italic>O</italic>-substituted products (Kabir, Matin, &#x00026; Kawsar, <xref rid="CIT0015" ref-type="bibr">1998</xref>; Kabir, Matin, Kawsar, &#x00026; Anwar, <xref rid="CIT0016" ref-type="bibr">1998</xref>; Kabir, Matin, Mridha, et al., <xref rid="CIT0017" ref-type="bibr">1998</xref>; Kabir et al., <xref rid="CIT0014" ref-type="bibr">1997</xref>, <xref rid="CIT0018" ref-type="bibr">1998a</xref>, <xref rid="CIT0015" ref-type="bibr">1998</xref>b, <xref rid="CIT0013" ref-type="bibr">2002</xref>). However, in most of the cases direct method gave higher yield(s) with lower cost (Matin, <xref rid="CIT0027" ref-type="bibr">2014</xref>; Matin et al., <xref rid="CIT0029" ref-type="bibr">2017</xref>). Chowdhury et al. (<xref rid="CIT0004" ref-type="bibr">2016</xref>) applied direct method with hindered 4-<italic>t</italic>-butylbenzoyl chloride in pyridine at &#x02212;5&#x02009;&#x000b0;C and afforded the 5&#x02032;-<italic>O</italic>-(4-<italic>t</italic>-butylbenzoyl)uridine (<bold>4</bold>) in excellent yield.</p><p>Now-a-days, emergence of multiple drug resistant (MDR) pathogenic organisms, and corona virus disease 2019 (COVID-19) are global concern (Ghosh et al., <xref rid="CIT0011" ref-type="bibr">2020</xref>; Lakshmi et al., <xref rid="CIT0021" ref-type="bibr">2020</xref>; Wahedi et al., <xref rid="CIT0045" ref-type="bibr">2020</xref>) in addition to numerous obstacles encountered on delivery to the site of microbial infection. Many researchers are engaged to overcome these situations (Awual, <xref rid="CIT0001" ref-type="bibr">2017</xref>; Laws et al., <xref rid="CIT0022" ref-type="bibr">2020</xref>; Matin, <xref rid="CIT0026" ref-type="bibr">2008</xref>; Sharavanan et al., <xref rid="CIT0041" ref-type="bibr">2020</xref>). However, there is urgent need for establishment of new chemotherapeutic agents with novel mode of action to combat with these MDR organisms, and SARS CoV-2 (severe acute respiratory syndrome corona virus-2). In this regard as well as our continuous effort to find novel drugs (Matin, <xref rid="CIT0027" ref-type="bibr">2014</xref>; Matin &#x00026; Ibrahim, <xref rid="CIT0035" ref-type="bibr">2010</xref>; Matin et al., <xref rid="CIT0031" ref-type="bibr">2015</xref>) we report herein the <italic>in vitro</italic> antimicrobial efficacy of several uridine-based esters <bold>4</bold>&#x02013;<bold>15</bold> with different aliphatic and aromatic chains against eleven pathogens, molecular docking against lanosterol 14&#x003b1;-demethylase (3LD6), <italic>A. flavus</italic> (1R51) and corona virus (SARS CoV-2) main protease (Mpro; 7BQY) along with prediction of activity spectra for substances (PASS). Also, attempts have been taken to optimize some acylated uridine derivatives to investigate their physicochemical behavior on the basis of DFT approach with cytotoxicity, and ADMET properties.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Material and methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Materials: uridine esters 4&#x02013;15</title><p>In our present study, twelve uridine-based esters with different side chain length and different groups <bold>4</bold>&#x02013;<bold>15</bold> were used as test chemicals. These compounds (mainly 5&#x02032;-<italic>O</italic>-<italic>t</italic>-butylbenzoyl esters of uridine), as presented in <xref ref-type="fig" rid="F0002">Figure 2</xref>, were synthesized from <bold>1</bold> by direct method and well characterized earlier (Chowdhury et al., <xref rid="CIT0004" ref-type="bibr">2016</xref>). For comparative study, uridine (<bold>1</bold>), standard antibacterial antibiotic ampicillin and antifungal antibiotic nystatin were also used.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Structures of <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><graphic content-type="black-white" xlink:href="TBSD_A_1850358_F0002_B"/></fig></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Pass predication</title><p>Web-based PASS (<ext-link ext-link-type="uri" xlink:href="http://www.pharmaexpert.ru/">http://www.pharmaexpert.ru/</ext-link> PASSonline/index.php) was used for the prediction of biological spectrum of these uridine derivatives (Matin et al., <xref rid="CIT0036" ref-type="bibr">2016</xref>). Initially, structures of the uridine esters were drawn, and then, converted into their SD file formats which were used to predict biological spectrum using PASS online software. This program is designed to anticipate a plethora of biological activities with 90% accuracy. PASS results are designated as Pa (probability for active compound) and Pi (probability for inactive compound). Being probabilities, the Pa and Pi values vary from 0.000 to 1.000 and in general, Pa&#x02009;+&#x02009;Pi &#x02260; 1, since these probabilities are calculated independently. Only the activities with Pa&#x02009;&#x0003e;&#x02009;Pi are considered as possible for a particular drug. The PASS prediction results were interpreted and used in a flexible manner, viz. (i) when Pa &#x0003e; 0.7, the chance to find the activity experimentally is high, (ii) if 0.5 &#x0003c; Pa &#x0003c; 0.7, the chance to find the activity experimentally is less, but the compound is probably not so similar to known pharmaceutical agents and (iii) if Pa &#x0003c; 0.5, the chance to find the activity experimentally is less, but the chance to find a structurally. So, the predicted activity of spectrum of a drug is known as its intrinsic property.</p></sec><sec id="S0002-S2003" disp-level="2"><title><italic>2.3.</italic> In vitro <italic>antimicrobial activity test</italic></title><sec id="S0002-S2003-S3001" disp-level="3"><label>2.3.1.</label><title>Test organisms</title><p>The tested microorganisms (bacteria and fungi) were collected from the Pharmacology laboratory, Department of Physiology, Biochemistry &#x00026; Pharmacology, Faculty of Veterinary Medicine, Chittagong Veterinary and Animal Science University, Chattogram, Bangladesh. As shown in <xref rid="t0001" ref-type="table">Table 1</xref>, nine human pathogenic bacteria and three plant pathogenic fungi were used for the antimicrobial evaluation.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Name of the pathogenic microorganisms.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Sl.</th><th align="center">Strain</th><th colspan="2" align="center">Reference</th><th align="center">Source</th></tr></thead><tbody valign="top"><tr><td colspan="2">Gram-positive bacteria</td><td colspan="2">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">(i)</td><td align="left"><italic toggle="yes">Bacillus cereus</italic></td><td colspan="2">BTCC 19</td><td align="left">Gastrointestinal tract</td></tr><tr><td align="left">(ii)</td><td align="left"><italic toggle="yes">Bacillus megaterium</italic></td><td colspan="2">BTCC 18</td><td align="left">Clinical strains</td></tr><tr><td align="left">(iii)</td><td align="left"><italic toggle="yes">Bacillus subtilis</italic></td><td colspan="2">BTCC 17</td><td align="left">Gastrointestinal tract</td></tr><tr><td align="left">(iv)</td><td align="left"><italic toggle="yes">Staphylococcus aureus</italic></td><td colspan="2">ATCC 6538</td><td align="left">Dairy cows</td></tr><tr><td colspan="5">Gram-negative bacteria</td></tr><tr><td align="left">(v)</td><td align="left"><italic toggle="yes">Escherichia coli</italic></td><td colspan="2">ATCC 25922</td><td align="left">Clinical isolate</td></tr><tr><td align="left">(vi)</td><td align="left"><italic toggle="yes">Shigella dysenteriae</italic></td><td colspan="2">AE 14369</td><td align="left">Milk &#x00026; dairy products</td></tr><tr><td align="left">(vii)</td><td align="left"><italic toggle="yes">Salmonella paratyphi</italic></td><td colspan="2">ATCC 11511</td><td align="left">Clinical isolate</td></tr><tr><td align="left">(viii)</td><td align="left"><italic toggle="yes">Salmonella typhi</italic></td><td colspan="2">AE 14612</td><td align="left">Raw meat</td></tr><tr><td align="left">(ix)</td><td align="left"><italic toggle="yes">Vibrio cholera</italic></td><td colspan="2">ICDDR, B</td><td align="left">Stool sample</td></tr><tr><td colspan="3">Name of the fungi</td><td colspan="2">Type of organism</td></tr><tr><td align="left">(i)</td><td colspan="2"><italic toggle="yes">Aspergillus acheraccus</italic></td><td colspan="2">Human pathogenic</td></tr><tr><td align="left">(ii)</td><td colspan="2"><italic toggle="yes">Aspergillus flavus</italic></td><td colspan="2">Human pathogenic</td></tr><tr><td align="left">(iii)</td><td colspan="2"><italic toggle="yes">Macrophomina phaseolina</italic></td><td colspan="2">Human pathogenic</td></tr></tbody></table></table-wrap></sec><sec id="S0002-S2003-S3002" disp-level="3"><label>2.3.2.</label><title>Screening of antibacterial activity</title><p><italic>In vitro</italic> antibacterial activities of uridine <bold>4</bold>&#x02013;<bold>15</bold> were conducted by paper disc diffusion method (Kabir et al., <xref rid="CIT0012" ref-type="bibr">2003</xref>; Matin et al., <xref rid="CIT0030" ref-type="bibr">2013</xref>), which was determined by the presence or absence of diameter of zone of inhibition (in mm). In this method, initially a 2% solution of the uridine compound(s) in DMF was prepared. Mueller-Hinton (agar and broth) medium was used to culture the bacteria. Paper disc of 4&#x02009;mm in a diameter and petri plate of 70&#x02009;mm in a diameter was used throughout the experiment. These paper discs were sterilized in an autoclave and dried at 150&#x02009;&#x000b0;C in an electric oven. Then, the discs were socked with test compound(s) at the rate of 100&#x02009;&#x003bc;g (dry weight) per disc. These paper discs were put in the petri-plates and were incubated at 37&#x02009;&#x000b0;C for 48&#x02009;h for growth of test organisms followed by the cooling for 4&#x02009;h at low temperature (4&#x02009;&#x000b0;C). The test chemicals diffused from disc to the surrounding medium by this time. The growth inhibition was calculated at 24&#x02009;h intervals for two days. Each experiment was carried out three times. All the results were compared with the standard antibacterial antibiotic ampicillin (50&#x02009;&#x003bc;g/disc, brand name Decapen, Beximco Pharmaceuticals Ltd., Bangladesh). Ampicillin was also used as a positive control and proper control was maintained with DMF without chemicals under identical conditions.</p></sec><sec id="S0002-S2003-S3003" disp-level="3"><label>2.3.3.</label><title>Screening of mycelial growth</title><p>The <italic>in vitro</italic> antifungal screening of the synthesized uridine derivatives (<bold>4</bold>&#x02013;<bold>15</bold>) were investigated employing food poisoning technique (Kabir, Matin, &#x00026; Kawsar, <xref rid="CIT0015" ref-type="bibr">1998</xref>; Kabir, Matin, Kawsar, &#x00026; Anwar, <xref rid="CIT0016" ref-type="bibr">1998</xref>; Kabir, Matin, Mridha, et al., <xref rid="CIT0017" ref-type="bibr">1998</xref>; Kabir et al., <xref rid="CIT0018" ref-type="bibr">1998a</xref>, <xref rid="CIT0015" ref-type="bibr">1998</xref>b; Matin, <xref rid="CIT0027" ref-type="bibr">2014</xref>). Sabouraud potato dextrose agar (PDA, agar and broth) medium was used for the culture of fungi. Necessary amount of medium was taken in a conical flask separately and was sterilized in an autoclave (at 121&#x02009;&#x000b0;C and 15&#x02009;psi) for 15&#x02009;min. After autoclaving, weighed amount of test chemical (2% in DMF) was added to the sterilized medium in conical flask at the point of pouring to obtain desired concentration. The flask was shaken thoroughly to mix the chemical with the medium homogeneously before pouring. The medium with definite concentration (2%) of chemical was poured at the rate of 100&#x02009;&#x003bc;g/mL PDA in sterilized glass petri dishes individually and subjected for incubation. Finally, linear mycelial growth of fungus was measured after 2&#x02013;5&#x02009;days (24&#x02009;h interval) of incubation. The percentage of radial mycelial growth inhibition of the test fungus was calculated using the following equation:
<disp-formula id="M0001"><alternatives><graphic xlink:href="TBSD_A_1850358_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d2e699"><mml:mrow><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">{</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>T</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mi>C</mml:mi></mml:mfrac></mml:mrow><mml:mo stretchy="true">}</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></alternatives></disp-formula></p><p>Where, <italic>I</italic> = percentage of inhibition, <italic>C</italic> = diameter of the fungal colony in control (DMF), <italic>T</italic> = diameter of the fungal colony in treatment. In all the cases, the results were compared with standard antifungal antibiotic nystatin (100&#x02009;&#x003bc;g/mL medium, brand name Fungistin, Beximco Pharmaceuticals Ltd., Bangladesh). Proper control was maintained separately and with sterilized PDA medium without chemical and three replications were prepared for each treatment.</p></sec></sec><sec id="S0002-S2004" disp-level="2"><label>2.4.</label><title>Computational details: DFT</title><p>Quantum mechanical (QM) methods has gained attention on calculation of thermodynamic properties, molecular orbital features, dipole moment and as well as interpretation of different types of interactions. Molecular geometry optimization and further modification of all uridine derivatives carried out using Gaussian 16 program. All the structures were optimized using density functional theory (DFT) employing Becke&#x02019;s (B) three-parameter hybrid model, Lee, Yang and Parr&#x02019;s (LYP) correlation functional under 3-21G basis set (Kruse et al., <xref rid="CIT0020" ref-type="bibr">2012</xref>). Initial optimization of all compounds was performed in the gas phase. Dipole moment, electronic energy, enthalpy and free energy are calculated for all the compounds.</p><p>Frontier molecular orbital features HOMO (highest occupied molecular orbital), LUMO (lowest unoccupied molecular orbital) were calculated at the same level of theory. For each of the structure HOMO-LUMO gap(&#x00394;<italic>&#x003b5;</italic>), hardness (<italic>&#x003b7;</italic>), softness (<italic>S</italic>) and chemical potential (<italic>&#x000b5;</italic>) were calculated from the energies of frontier HOMO and LUMO as reported considering Parr and Pearson interpretation of DFT and Koopmans theorem (Pearson, <xref rid="CIT0039" ref-type="bibr">1986</xref>) on the correlation of ionization potential and electron affinities with HOMO and LUMO energy (<italic>&#x003b5;</italic>). Hardness (<italic>&#x003b7;</italic>), softness (<italic>S</italic>) and chemical potential (<italic>&#x000b5;</italic>) are calculated by using the following equations:
<disp-formula id="M0002"><alternatives><graphic xlink:href="TBSD_A_1850358_M0002.jpg" position="float" orientation="portrait"/><mml:math id="d2e775"><mml:mrow><mml:mtext>Gap</mml:mtext><mml:mi mathvariant="normal">
</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#x00394;</mml:mo><mml:mi>&#x003b5;</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mi mathvariant="normal">
</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>&#x003b5;</mml:mi><mml:mtext>LUMO</mml:mtext><mml:mi mathvariant="normal">
</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mi>&#x003b5;</mml:mi><mml:mtext>HOMO</mml:mtext></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mi>&#x003b7;</mml:mi><mml:mi mathvariant="normal">
</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>&#x003b5;</mml:mi><mml:mtext>LUMO</mml:mtext><mml:mi mathvariant="normal">
</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mi>&#x003b5;</mml:mi><mml:mtext>HOMO</mml:mtext></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo>;</mml:mo><mml:mtext> S </mml:mtext><mml:mo>=</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>&#x003b7;</mml:mi><mml:mo>;</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mi>&#x003bc;</mml:mi><mml:mi mathvariant="normal">
</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>&#x003b5;</mml:mi><mml:mtext>LUMO</mml:mtext><mml:mi mathvariant="normal">
</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mi>&#x003b5;</mml:mi><mml:mtext>HOMO</mml:mtext></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></alternatives></disp-formula></p><sec id="S0002-S2004-S3001" disp-level="3"><label>2.4.1.</label><title>Protein preparation and visualization</title><p>The 3D crystal structure of main protease of COVID-19 (7BQY), lanosterol 14&#x003b1;-demethylase (3LD6/CYP51A1) and <italic>A. flavus</italic> (1R51) was obtained in pdb format from online protein data bank (PDB) database (Lucido et al., <xref rid="CIT0025" ref-type="bibr">2016</xref>). All hetero atoms, inhibitors and water molecules were erased using PyMol (version 1.3) software packages. Energy minimization of the protein implemented by Swiss-Pdb viewer software (version 4.1.0) (Matin, Chakraborty, et al., <xref rid="CIT0033" ref-type="bibr">2020</xref>; Matin, Hasan, et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>; Matin, Roshid, et al., <xref rid="CIT0037" ref-type="bibr">2020</xref>). The optimized structures were subjected for molecular docking study against 7BQY, CYP51A1 and 1R51 considering the protein as macromolecule and uridine esters as ligand. Finally, rigid docking simulation was performed by PyRx software (version 0.8) targeting the active site with the center grid box size 48.8375, 65.6838, 59.1841&#x02009;&#x000c5; for 7BQY; 61.8544, 61.1656, 70.6697&#x02009;&#x000c5; for 3LD6; and 58.4699, 69.9558, 58.3507&#x02009;&#x000c5; for 15R1 along <italic>x</italic>, <italic>y</italic> and <italic>z</italic> directions, respectively. After docking, Accelrys Discovery Studio (version 4.1) software was utilized to analyze and visualize the docking results (Wahedi et al., <xref rid="CIT0045" ref-type="bibr">2020</xref>). Docking results are basically calculated as binding affinities of ligand-protease and reported in kcal/mol unit.</p></sec></sec><sec id="S0002-S2005" disp-level="2"><label>2.5.</label><title>Toxic activity test</title><p>For the determination of toxicity of the uridine derivatives we employed brine shrimp lethality assay technique as described by McLaughlin (<xref rid="CIT0038" ref-type="bibr">1991</xref>). The tested compounds were dissolved in DMSO, and prepared 20, 40, 80 and 160&#x02009;&#x003bc;L by adding NaCl solution to each vial up to 1&#x02009;mL volume which were designated as type- A, B, C and D, respectively. Three sets of experiment were done for each concentration and 10 brine shrimps nauplii were placed in each vial. A control experiment was performed in a vial containing 10 nauplii in 1&#x02009;mL seawater. After 24&#x02009;h and 48&#x02009;h of incubation at room temperature, the vials were observed using a magnifying glass and the number of survivors in each vial was counted and noted. From the data, the average percentage of mortality of nauplii was calculated for each concentration. No deaths were found for controls.</p></sec><sec id="S0002-S2006" disp-level="2"><label>2.6.</label><title>ADMET calculation</title><p>Online computational approaches were made to predict absorption, distribution, metabolism, excretion and toxicity (ADMET) for 5&#x02032;-<italic>O</italic>-(4-<italic>t</italic>-butylbenzoyl)uridine (<bold>4</bold>) and its 2&#x02032;,3&#x02032;-di-<italic>O</italic>-acyl derivatives <bold>5</bold>&#x02013;<bold>15</bold> (Matin, Chakraborty, et al., <xref rid="CIT0033" ref-type="bibr">2020</xref>; Matin, Hasan, et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>; Matin, Roshid, et al., <xref rid="CIT0037" ref-type="bibr">2020</xref>). The computational prediction of drug could avoid the tremendous cost and time associated with the <italic>in vivo</italic> experiments, and has attracted more and more attention. In the present study, we utilized <italic>in silico</italic> screening approaches employing pkCSM server (<ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au">http://biosig.unimelb.edu.au</ext-link>). The pkCSM signatures were successfully used across five main different pharmacokinetic property classes to develop predictive regression and classification models (Pires et al., <xref rid="CIT0040" ref-type="bibr">2015</xref>). Firstly, all the structures of uridine esters were drawn in ChemDraw 16.0 to collect InChI Key, isomeric SMILES (simplified molecular-input line-entry system), and SD file format. ADMET of all the uridine esters were predicted by using pkCSM-pharmacokinetics and SwissADME free web tools (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch">http://www.swissadme.ch</ext-link>).</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><p>In the present study, twelve uridine esters with different aliphatic and aromatic chains (<bold>4&#x02013;15</bold>) were selected as test compounds, and screened for their <italic>in vitro</italic> antibacterial and antifungal activities against nine bacteria and, and three phytopathogenic fungi, respectively. Initially, we predicted these activities using PASS program followed by <italic>in vitro</italic> determination. The observed activities were then rationalized by calculating their physicochemical (DFT method), cytotoxicity (shrimp), molecular docking and ADMET properties. Finally, all these findings were used to summarize their structure&#x02013;activity relationship (SAR).</p><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Computational-based biological activities: PASS</title><p>Having all the uridine esters <bold>4</bold>&#x02013;<bold>15</bold>, we predicted their biological spectrum using online PASS software (<ext-link ext-link-type="uri" xlink:href="http://www.pharmaexpert.ru/">http://www.pharmaexpert.ru/</ext-link> PASSonline/index.php). The PASS results in its designated as Pa and Pi form is presented in <xref rid="t0002" ref-type="table">Table 2</xref>.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Predicted biological activity of the uridine-based esters <bold>4</bold>&#x02013;<bold>15</bold> using PASS software.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="3" align="left">Drug</th><th colspan="8" align="center">Biological activity<hr/></th></tr><tr><th colspan="2" align="center">Antibacterial<hr/></th><th colspan="2" align="center">Antifungal<hr/></th><th colspan="2" align="center">Anti-carcinogenic<hr/></th><th colspan="2" align="center">Antioxidant<hr/></th></tr><tr><th align="center">Pa</th><th align="center">Pi</th><th align="center">Pa</th><th align="center">Pi</th><th align="center">Pa</th><th align="center">Pi</th><th align="center">Pa</th><th align="center">Pi</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">0.397</td><td align="center">0.031</td><td align="center">0.421</td><td align="center">0.046</td><td align="center">0.785</td><td align="center">0.006</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">0.320</td><td align="center">0.053</td><td align="center">0.437</td><td align="center">0.042</td><td align="center">0.667</td><td align="center">0.010</td><td align="center">0.168</td><td align="center">0.081</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">0.348</td><td align="center">0.044</td><td align="center">0.486</td><td align="center">0.033</td><td align="center">0.668</td><td align="center">0.010</td><td align="center">0.156</td><td align="center">0.095</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">0.180</td><td align="center">0.137</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">0.407</td><td align="center">0.030</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">0.327</td><td align="center">0.050</td><td align="center">0.526</td><td align="center">0.027</td><td align="center">0.621</td><td align="center">0.012</td><td align="center">0.158</td><td align="center">0.093</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">0.327</td><td align="center">0.050</td><td align="center">0.526</td><td align="center">0.027</td><td align="center">0.621</td><td align="center">0.012</td><td align="center">0.158</td><td align="center">0.093</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">0.327</td><td align="center">0.050</td><td align="center">0.526</td><td align="center">0.027</td><td align="center">0.621</td><td align="center">0.012</td><td align="center">0.158</td><td align="center">0.093</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">0.327</td><td align="center">0.050</td><td align="center">0.526</td><td align="center">0.027</td><td align="center">0.621</td><td align="center">0.012</td><td align="center">0.158</td><td align="center">0.093</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">0.327</td><td align="center">0.050</td><td align="center">0.526</td><td align="center">0.027</td><td align="center">0.621</td><td align="center">0.012</td><td align="center">0.158</td><td align="center">0.093</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">0.327</td><td align="center">0.050</td><td align="center">0.526</td><td align="center">0.027</td><td align="center">0.621</td><td align="center">0.012</td><td align="center">0.158</td><td align="center">0.093</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">0.193</td><td align="center">0.125</td><td align="center">0.436</td><td align="center">0.042</td><td align="center">0.482</td><td align="center">0.021</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">0.213</td><td align="center">0.106</td><td align="center">0.441</td><td align="center">0.041</td><td align="center">0.515</td><td align="center">0.018</td><td align="center">0.132</td><td align="center">0.124</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">0.163</td><td align="center">0.152</td><td align="center">0.389</td><td align="center">0.052</td><td align="center">0.467</td><td align="center">0.022</td><td align="center">0.431</td><td align="center">0.10</td></tr><tr><td align="left"><bold>APC</bold></td><td align="center">0.750</td><td align="center">0.003</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>NYS</bold></td><td align="center">0.967</td><td align="center">0.00</td><td align="center">0.986</td><td align="center">0.00</td><td align="center">0.416</td><td align="center">0.028</td><td align="center">0.145</td><td align="center">0.108</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Pa: probability &#x02018;to be active&#x02019;; Pi: probability &#x02018;to be inactive&#x02019;; APC: ampicillin; NYS: nystatin.</p></fn></table-wrap-foot></table-wrap><p>It was evident from predication <xref rid="t0002" ref-type="table">Table 2</xref> for uridine esters <bold>4</bold>&#x02013;<bold>15</bold> showed 0.16 &#x0003c; Pa &#x0003c; 0.35 for antibacterial and 0.38 &#x0003c; Pa &#x0003c; 0.53 for antifungal. This clearly indicated that these compounds were more prone against fungi as compared to that of bacterial pathogens. Also, incorporation of mesyl groups, as in compound <bold>6</bold>, totally abolished antifungal potentiality of uridine. Addition of aliphatic acyl chains (C2 to C16, compound <bold>5</bold>, <bold>7</bold>&#x02013;<bold>12</bold>) increased antifungal activity (Pa = 0.526) of uridine (<bold>1</bold>, Pa = 0.421), whereas attachment of chloro-substituted benzoyl groups did not enhance reasonably (<bold>13</bold>&#x02013;<bold>15</bold>, Pa = 0.389&#x02013;0.436). We have also calculated anti-carcinogenic and antioxidant property of these compounds. Thus, PASS predication showed 0.46 &#x0003c; Pa &#x0003c; 0.67 for anti-carcinogenic and 0.13 &#x0003c; Pa &#x0003c; 0.43 for antioxidant, which indicated that the uridine esters were more potent as anti-carcinogenic agents than that of antioxidant properties. Interestingly, the results as shown in <xref rid="t0002" ref-type="table">Table 2</xref>, antifungal and anti-carcinogenic properties of uridine esters with saturated aliphatic chains (<bold>5</bold>, <bold>7</bold>&#x02013;<bold>12</bold>) were found more promising than the sulphonyl ester (<bold>6</bold>) or chloro-substituted benzoyl derivatives (<bold>13</bold>&#x02013;<bold>15</bold>). These results are in agreement with our previous study for monosaccharide esters (Matin, Chakraborty, et al., <xref rid="CIT0033" ref-type="bibr">2020</xref>; Matin, Hasan, et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>; Matin, Roshid, et al., <xref rid="CIT0037" ref-type="bibr">2020</xref>).</p></sec><sec id="S0003-S2002" disp-level="2"><title><italic>3.2.</italic> In vitro <italic>antimicrobial activities</italic></title><sec id="S0003-S2002-S3001" disp-level="3"><label>3.2.1.</label><title>Antibacterial potentiality of <bold>4</bold>&#x02013;<bold>15</bold></title><p>For the <italic>in vitro</italic> antibacterial efficacy test we followed disc diffusion method (Kabir et al., <xref rid="CIT0012" ref-type="bibr">2003</xref>). The results of diameter of inhibition zone (mm) of the uridine-based esters <bold>4</bold>&#x02013;<bold>15</bold> against four Gram-positive, and five Gram-negative bacteria are presented in <xref rid="t0003" ref-type="table">Table 3</xref> (<xref ref-type="fig" rid="F0003">Figure 3</xref>) and <xref rid="t0004" ref-type="table">Table 4</xref> (<xref ref-type="fig" rid="F0004">Figure 4</xref>). It was evident that these esters are less susceptible towards both the Gram-positive and Gram-negative pathogens, and similar results were reported for other uridine esters (Kabir, Matin, &#x00026; Kawsar, <xref rid="CIT0015" ref-type="bibr">1998</xref>; Kabir, Matin, Kawsar, &#x00026; Anwar, <xref rid="CIT0016" ref-type="bibr">1998</xref>; Kabir, Matin, Mridha, et al., <xref rid="CIT0017" ref-type="bibr">1998</xref>; Kabir et al., <xref rid="CIT0018" ref-type="bibr">1998a</xref>, <xref rid="CIT0015" ref-type="bibr">1998</xref>b). Amongst the uridine derivatives, compound <bold>8</bold> (C6 chain) and <bold>10</bold> (C12 chain) showed moderate inhibition against <italic>B. megaterium</italic>, <italic>S. dysenteriae</italic> and <italic>V. cholerae</italic>. Also, mesyl derivative <bold>6</bold> and chlorobenzoyl derivatives <bold>13</bold>&#x02013;<bold>15</bold> showed very little antibacterial functionality which is in agreement with the PASS results (<xref rid="t0002" ref-type="table">Table 2</xref>). In general, compounds <bold>4</bold>&#x02013;<bold>15</bold> were found more prone against Gram-negative pathogens than the Gram-positive organisms.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>(a) Inhibition against Gram-positive bacteria; (b) Zone of inhibition observed against <italic>Bacillus Cereus</italic> by four test chemicals <bold>13</bold> (SO-10), <bold>14</bold> (K-7) and <bold>15</bold> (U-6).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0003_C"/></fig><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Inhibition against Gram-negative pathogens.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0004_C"/></fig><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Inhibition against Gram-positive pathogens by uridine esters.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Drug</th><th colspan="4" align="center">Diameter of zone of inhibition in mm (100 &#x000b5;g dw / disc)<hr/></th></tr><tr><th align="center"><italic toggle="yes">B. cereus</italic></th><th align="center"><italic toggle="yes">B. megaterium</italic></th><th align="center"><italic toggle="yes">B. subtilis</italic></th><th align="center"><italic toggle="yes">S. aureus</italic></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">13.6&#x02009;&#x000b1;&#x02009;0.39</td><td align="center">8.5&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">7.5&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">NI</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">NI</td><td align="center">6.1&#x02009;&#x000b1;&#x02009;0.28</td><td align="center">10.3&#x02009;&#x000b1;&#x02009;0.58</td><td align="center">9.0&#x02009;&#x000b1;&#x02009;0.34</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">NI</td><td align="center">7.4&#x02009;&#x000b1;&#x02009;0.44</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">NI</td><td align="center">6.6&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">NI</td><td align="center">10.3&#x02009;&#x000b1;&#x02009;0.38</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">NI</td><td align="center">9.1&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">NI</td><td align="center">8.5&#x02009;&#x000b1;&#x02009;0.58</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">NI</td><td align="center">12.0&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">NI</td><td align="center">7.0&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">7.0&#x02009;&#x000b1;&#x02009;0.66</td><td align="center">NI</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">NI</td><td align="center">6.6&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">NI</td><td align="center">6.5&#x02009;&#x000b1;&#x02009;0.45</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left">**<bold>AMP</bold></td><td align="center">*18.0&#x02009;&#x000b1;&#x02009;0.51</td><td align="center">*16.1&#x02009;&#x000b1;&#x02009;0.64</td><td align="center">*19.0&#x02009;&#x000b1;&#x02009;0.58</td><td align="center">*22.2&#x02009;&#x000b1;&#x02009;0.24</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>Data are presented as (Mean &#x000b1; <italic>SD</italic>).</p></fn><fn id="TF3"><p>*Significantly inhibition values.</p></fn><fn id="TF4"><p>**Reference antibiotic ampicillin (AMP; 50&#x02009;&#x000b5;g/disc).</p></fn><fn id="TF5"><p>dw: dry weight; NI: no inhibition; NI was observed for control DMF; Values are represented for the triplicate of all the experiments.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Inhibition against Gram-negative pathogens by <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Drug</th><th colspan="5" align="center">Diameter of zone of inhibition in mm (100 &#x000b5;g dw/disc)<hr/></th></tr><tr><th align="center"><italic toggle="yes">E. coli</italic></th><th align="center"><italic toggle="yes">S. dysenteriae</italic></th><th align="center"><italic toggle="yes">S. paratyphi</italic></th><th align="center"><italic toggle="yes">S. typhi</italic></th><th align="center"><italic toggle="yes">V. cholerae</italic></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">8.6&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">NI</td><td align="center">NI</td><td align="center">10.5&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">NI</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">7.5&#x02009;&#x000b1;&#x02009;0.44</td><td align="center">NI</td><td align="center">8.0&#x02009;&#x000b1;&#x02009;0.24</td><td align="center">*12.5&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">5.0&#x02009;&#x000b1;&#x02009;0.44</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">NI</td><td align="center">6.0&#x02009;&#x000b1;&#x02009;0.58</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">NI</td><td align="center">8.4&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">NI</td><td align="center">NI</td><td align="center">6.1&#x02009;&#x000b1;&#x02009;0.33</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">6.6&#x02009;&#x000b1;&#x02009;0.33</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">NI</td><td align="center">*13.8&#x02009;&#x000b1;&#x02009;0.38</td><td align="center">*12.8&#x02009;&#x000b1;&#x02009;0.83</td><td align="center">NI</td><td align="center">8.2&#x02009;&#x000b1;&#x02009;0.54</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">9.5&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">6.7&#x02009;&#x000b1;&#x02009;0.71</td><td align="center">7.8&#x02009;&#x000b1;&#x02009;0.58</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">11.5&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">7.0&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">8.0&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">NI</td><td align="center">*12.5&#x02009;&#x000b1;&#x02009;0.50</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">NI</td><td align="center">9.8&#x02009;&#x000b1;&#x02009;0.68</td><td align="center">NI</td><td align="center">NI</td><td align="center">9.0&#x02009;&#x000b1;&#x02009;0.50</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">7.7&#x02009;&#x000b1;&#x02009;0.64</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">9.0&#x02009;&#x000b1;&#x02009;0.71</td><td align="center">10.1&#x02009;&#x000b1;&#x02009;0.64</td><td align="center">NI</td><td align="center">NI</td><td align="center">10.3&#x02009;&#x000b1;&#x02009;0.71</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">7.0&#x02009;&#x000b1;&#x02009;0.48</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left">**<bold>AMP</bold></td><td align="center">*10.9&#x02009;&#x000b1;&#x02009;0.49</td><td align="center">*22.1&#x02009;&#x000b1;&#x02009;0.68</td><td align="center">*18.0&#x02009;&#x000b1;&#x02009;0.58</td><td align="center">*20.2&#x02009;&#x000b1;&#x02009;0.24</td><td align="center">*31.9&#x02009;&#x000b1;&#x02009;0.74</td></tr></tbody></table><table-wrap-foot><fn id="TF6"><p>Data are presented as (Mean &#x000b1; <italic>SD</italic>).</p></fn><fn id="TF7"><p>*Significantly inhibition values.</p></fn><fn id="TF8"><p>**Reference antibiotic ampicillin (AMP; 50&#x02009;&#x000b5;g/disc).</p></fn><fn id="TF9"><p>dw: dry weight; NI: no inhibition; NI was observed for control DMF; Values are represented for the triplicate of all the experiments.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Inhibition against fungal pathogens by <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Drug</th><th colspan="3" align="center">% Inhibition of fungal mycelial growth (100 &#x000b5;g dw/mL PDA)<hr/></th></tr><tr><th align="center"><italic toggle="yes">A. acheraccus</italic></th><th align="center"><italic toggle="yes">A. flavus</italic></th><th align="center"><italic toggle="yes">M. phaseolina</italic></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">25.3&#x02009;&#x000b1;&#x02009;0.28</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">6.9&#x02009;&#x000b1;&#x02009;0.24</td><td align="center">NI</td><td align="center">38.4&#x02009;&#x000b1;&#x02009;0.38</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">18.7&#x02009;&#x000b1;&#x02009;0.64</td><td align="center">NI</td><td align="center">*57.8&#x02009;&#x000b1;&#x02009;0.64</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">17.5&#x02009;&#x000b1;&#x02009;0.54</td><td align="center">NI</td><td align="center">NI</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">19.0&#x02009;&#x000b1;&#x02009;0.24</td><td align="center">NI</td><td align="center">52.3&#x02009;&#x000b1;&#x02009;0.64</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">NI</td><td align="center">34.2&#x02009;&#x000b1;&#x02009;0.64</td><td align="center">*58.1&#x02009;&#x000b1;&#x02009;0.50</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">10.7&#x02009;&#x000b1;&#x02009;0.44</td><td align="center">15.2&#x02009;&#x000b1;&#x02009;0.84</td><td align="center">NI</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">34.3&#x02009;&#x000b1;&#x02009;0.48</td><td align="center">25.8&#x02009;&#x000b1;&#x02009;0.28</td><td align="center">*69.2&#x02009;&#x000b1;&#x02009;0.50</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">NI</td><td align="center">28.0&#x02009;&#x000b1;&#x02009;0.50</td><td align="center">48.0&#x02009;&#x000b1;&#x02009;0.84</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">14.0&#x02009;&#x000b1;&#x02009;0.29</td><td align="center">NI</td><td align="center">41.0&#x02009;&#x000b1;&#x02009;0.54</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">8.0&#x02009;&#x000b1;&#x02009;0.24</td><td align="center">NI</td><td align="center">46.1&#x02009;&#x000b1;&#x02009;0.83</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">9.1&#x02009;&#x000b1;&#x02009;0.64</td><td align="center">5.5&#x02009;&#x000b1;&#x02009;0.33</td><td align="center">*72.0&#x02009;&#x000b1;&#x02009;0.68</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">NI</td><td align="center">NI</td><td align="center">*73.1&#x02009;&#x000b1;&#x02009;0.84</td></tr><tr><td align="left">**NYS</td><td align="center">22.0&#x02009;&#x000b1;&#x02009;0.25</td><td align="center">26.1&#x02009;&#x000b1;&#x02009;0.29</td><td align="center">*71.8&#x02009;&#x000b1;&#x02009;0.58</td></tr></tbody></table><table-wrap-foot><fn id="TF10"><p>Data are presented as (Mean &#x000b1; <italic>SD</italic>).</p></fn><fn id="TF11"><p>*Significant inhibition.</p></fn><fn id="TF12"><p>**Reference antibiotic nystatin NYS, 100&#x02009;&#x000b5;g/mL PDA.</p></fn><fn id="TF13"><p>dw: dry weight; NI: no inhibition; NI was observed for control DMF; Values are represented for the triplicate of all the experiments.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0003-S2002-S3002" disp-level="3"><label>3.2.2.</label><title>Antifungal susceptibility of 4&#x02013;15</title><p>The susceptibility of uridine esters <bold>4</bold>&#x02013;<bold>15</bold> against three pathogenic fungi are presented in <xref rid="t0004" ref-type="table">Table 5</xref>. The results, as presented in percentage inhibitions of mycelial growth, indicated that these compounds were more prone against tested fungal pathogens compared to bacterial organisms. Among the tested fungi, <bold>4</bold>&#x02013;<bold>15</bold> were more susceptible against <italic>M. phaseolina</italic>. Aliphatic chain containing compound <bold>5</bold> (C2, 57.8%, <xref ref-type="fig" rid="F0005">Figure 5</xref>), <bold>8</bold> (C6, 58.1%) and <bold>10</bold> (C12, 69.2%) exhibited very good percentage of inhibition against this fungus. To our surprise, chlorobenzoyl ester <bold>14</bold> (*72%) and <bold>15</bold> (*73.1%) showed excellent inhibition against <italic>M. phaseolina</italic> and the results were comparable to nystatin (*71.8%) in contrast to their antibacterial and PASS results.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>(a) Fungal inhibition by the uridine esters; (b) % Inhibition of mycelial growth of <italic>A. acheraccus</italic> by the <bold>5</bold> (U-7).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0005_C"/></fig></sec></sec><sec id="S0003-S2003" disp-level="2"><label>3.3.</label><title>Thermodynamic analysis</title><p>The molecular structure significantly influences the structural properties such as free energy (<italic>G</italic>), enthalpy (<italic>H</italic>), dipole moment and electrostatic potential. Spontaneity of a reaction and stability of a product can be predicted from Gibb&#x02019;s free energy, enthalpy and electronic energy. Free energy (<italic>G</italic>) is a significant criterion to represent the interaction of binding partners, where negative value favorable for spontaneous binding and interaction. Greater negative values predict better thermodynamic properties. In the present study, all the uridine esters possess greater negative value for <italic>E</italic>, <italic>H</italic> and <italic>G</italic> than the parent uridine, and hence, indicated that the attachment of ester group could improve interaction and binding of these molecules with different microbial enzymes. Due to these higher values (&#x02013;2990 to &#x02013;3903 Hartree) chlorobenzoyl esters <bold>14</bold>&#x02013;<bold>15</bold> exhibited better inhibition against <italic>M. phaseolina</italic>. In addition, these increased negative values of compound <bold>4&#x02013;15</bold> suggested that these are energetically and configurationally more stable.</p><p>As shown in <xref rid="t0005" ref-type="table">Table 6</xref>, some of the uridine esters have improved dipole moment. Improved dipole moment enhances the polar nature of a molecule, and promotes the binding affinity, hydrogen bonding and nonbonding interaction with the receptor protein (Lien et al., <xref rid="CIT0023" ref-type="bibr">1982</xref>). The dipole moment of compound <bold>4</bold> was 7.588 Debye and for compound <bold>15</bold> was 7.619 Debye which were slightly higher than the uridine (7.339 Debye) resulting their better binding affinity and interactions with the amino acid residues of receptor protein.</p><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Molecular formula, molecular weight, electronic energy (<italic>E</italic>), enthalpy (<italic>H</italic>), Gibb&#x02019;s free energy (<italic>G</italic>) in Hartree and dipole moment (<italic>&#x000b5;</italic>, Debye) of uridine derivatives.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Drug</th><th align="center">MF</th><th align="center">MW</th><th align="center"><italic toggle="yes">E</italic></th><th align="center"><italic toggle="yes">H</italic></th><th align="center"><italic toggle="yes">G</italic></th><th align="center"><italic toggle="yes">&#x003bc;</italic></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="left">C<sub>9</sub>H<sub>12</sub>N<sub>2</sub>O<sub>6</sub></td><td align="left">244.201</td><td align="left">&#x02013;900.579</td><td align="left">&#x02013;900.578</td><td align="left">&#x02013;900.635</td><td align="char" char=".">7.339</td></tr><tr><td align="left"><bold>4</bold></td><td align="left">C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>7</sub></td><td align="left">404.414</td><td align="left">&#x02013;1396.029</td><td align="left">&#x02013;1396.028</td><td align="left">&#x02013;1396.113</td><td align="char" char=".">7.588</td></tr><tr><td align="left"><bold>5</bold></td><td align="left">C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">488.487</td><td align="left">&#x02013;1697.825</td><td align="left">&#x02013;1697.824</td><td align="left">&#x02013;1697.924</td><td align="char" char=".">3.865</td></tr><tr><td align="left"><bold>6</bold></td><td align="left">C<sub>22</sub>H<sub>28</sub>N<sub>2</sub>O<sub>11</sub>S<sub>2</sub></td><td align="left">560.595</td><td align="left">&#x02013;2562.166</td><td align="left">&#x02013;2562.165</td><td align="left">&#x02013;2562.270</td><td align="char" char=".">5.001</td></tr><tr><td align="left"><bold>7</bold></td><td align="left">C<sub>30</sub>H<sub>40</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">572.647</td><td align="left">&#x02013;1930.556</td><td align="left">&#x02013;1930.555</td><td align="left">&#x02013;1930.676</td><td align="char" char=".">4.123</td></tr><tr><td align="left"><bold>8</bold></td><td align="left">C<sub>32</sub>H<sub>44</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">600.700</td><td align="left">&#x02013;2008.131</td><td align="left">&#x02013;2008.130</td><td align="left">&#x02013;2008.257</td><td align="char" char=".">4.166</td></tr><tr><td align="left"><bold>9</bold></td><td align="left">C<sub>40</sub>H<sub>60</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">712.912</td><td align="left">&#x02013;2318.429</td><td align="left">&#x02013;2318.428</td><td align="left">&#x02013;2318.583</td><td align="char" char=".">4.230</td></tr><tr><td align="left"><bold>10</bold></td><td align="left">C<sub>44</sub>H<sub>68</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">769.019</td><td align="left">&#x02013;2473.580</td><td align="left">&#x02013;2473.579</td><td align="left">&#x02013;2473.746</td><td align="char" char=".">2.274</td></tr><tr><td align="left"><bold>11</bold></td><td align="left">C<sub>48</sub>H<sub>76</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">825.125</td><td align="left">&#x02013;2628.727</td><td align="left">&#x02013;2628.726</td><td align="left">&#x02013;2628.909</td><td align="char" char=".">4.249</td></tr><tr><td align="left"><bold>12</bold></td><td align="left">C<sub>52</sub>H<sub>84</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">881.231</td><td align="left">&#x02013;2783.876</td><td align="left">&#x02013;2783.875</td><td align="left">&#x02013;2784.072</td><td align="char" char=".">4.253</td></tr><tr><td align="left"><bold>13</bold></td><td align="left">C<sub>34</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">681.516</td><td align="left">&#x02013;2990.069</td><td align="left">&#x02013;2990.068</td><td align="left">&#x02013;2990.189</td><td align="char" char=".">6.206</td></tr><tr><td align="left"><bold>14</bold></td><td align="left">C<sub>34</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">681.516</td><td align="left">&#x02013;2990.070</td><td align="left">&#x02013;2990.069</td><td align="left">&#x02013;2990.190</td><td align="char" char=".">6.300</td></tr><tr><td align="left"><bold>15</bold></td><td align="left">C<sub>34</sub>H<sub>28</sub>Cl<sub>4</sub>N<sub>2</sub>O<sub>9</sub></td><td align="left">750.406</td><td align="left">&#x02013;3903.457</td><td align="left">&#x02013;3903.456</td><td align="left">&#x02013;3903.584</td><td align="char" char=".">7.619</td></tr></tbody></table></table-wrap><sec id="S0003-S2003-S3001" disp-level="3"><label>3.3.1.</label><title>Frontier molecular orbital analysis</title><p>The HOMO and LUMO energies, HOMO-LUMO gap (&#x00394;&#x0fffd;&#x0fffd;&#x0fffd;&#x0fffd;), hardness (<italic>&#x003b7;</italic>), softness (<italic>S</italic>) and chemical potential (<italic>&#x000b5;</italic>) index of all compounds are presented in <xref rid="t0006" ref-type="table">Table 7</xref> (<xref ref-type="fig" rid="F0006">Figure 6</xref>). According to the frontier molecular orbital theory, energies of HOMO and LUMO play an important role in chemical reactivity. The HOMO-LUMO gap is also related to the chemical hardness, softness, chemical potential and electrophilic index of a molecule (Cohen &#x00026; Benson, <xref rid="CIT0006" ref-type="bibr">1993</xref>; Lien et al., <xref rid="CIT0023" ref-type="bibr">1982</xref>). Large HOMO-LUMO gap is responsible for high kinetic stability and low chemical reactivity. On the other hand, small HOMO-LUMO gap is important for low chemical stability, because addition of electrons to a high-lying LUMO and/or removal of electrons from a low-lying HOMO is energetically favorable in any potential reaction. In these esters <bold>4</bold>&#x02013;<bold>15</bold>, &#x00394;&#x0fffd;&#x0fffd;&#x0fffd;&#x0fffd; value was found lower than uridine (<bold>1</bold>), and thus, favorable for energetically favorable reaction. We noticed that, with the increase of the number of ester group(s) and chain length (<bold>4</bold>&#x02013;<bold>15</bold>) hardness of these compounds gradually decreased while their softness gradually increased. All these properties may contribute to show higher chemical activity and polarizability in the drug related chemical and biochemical functionalities.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Frontier molecular orbital and related energy of uridine derivatives <bold>5</bold> and <bold>15</bold>.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0006_C"/></fig><table-wrap id="t0007" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Energy (eV) of HOMO, LUMO, Gap (&#x00394;&#x0fffd;&#x0fffd;&#x0fffd;&#x0fffd;), hardness (<italic>&#x003b7;</italic>), softness (<italic>S</italic>) and chemical potential (<italic>&#x003bc;</italic>) of uridine (<bold>1</bold>) and its esters <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Drug</th><th align="center">&#x02003;HOMO</th><th align="center">&#x02003;LUMO</th><th align="center">Gap (&#x00394;&#x0fffd;&#x0fffd;&#x0fffd;&#x0fffd;)</th><th align="center"><italic toggle="yes">&#x003b7;</italic></th><th align="center"><italic toggle="yes">S</italic></th><th align="center"><italic toggle="yes">&#x003bc;</italic></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="left">&#x02013;9.896</td><td align="left">2.848</td><td align="left">12.744</td><td align="left">6.372</td><td align="char" char=".">0.157</td><td align="left">&#x02013;3.524</td></tr><tr><td align="left"><bold>4</bold></td><td align="left">&#x02013;9.157</td><td align="left">2.812</td><td align="left">11.969</td><td align="left">5.985</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.173</td></tr><tr><td align="left"><bold>5</bold></td><td align="left">&#x02013;9.169</td><td align="left">2.777</td><td align="left">11.946</td><td align="left">5.973</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.196</td></tr><tr><td align="left"><bold>6</bold></td><td align="left">&#x02013;9.262</td><td align="left">2.638</td><td align="left">11.900</td><td align="left">5.950</td><td align="char" char=".">0.168</td><td align="left">&#x02013;3.312</td></tr><tr><td align="left"><bold>7</bold></td><td align="left">&#x02013;9.154</td><td align="left">2.798</td><td align="left">11.952</td><td align="left">5.976</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.178</td></tr><tr><td align="left"><bold>8</bold></td><td align="left">&#x02013;9.152</td><td align="left">2.801</td><td align="left">11.953</td><td align="left">5.977</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.176</td></tr><tr><td align="left"><bold>9</bold></td><td align="left">&#x02013;9.149</td><td align="left">2.804</td><td align="left">11.953</td><td align="left">5.977</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.173</td></tr><tr><td align="left"><bold>10</bold></td><td align="left">&#x02013;9.144</td><td align="left">2.811</td><td align="left">11.955</td><td align="left">5.978</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.167</td></tr><tr><td align="left"><bold>11</bold></td><td align="left">&#x02013;9.148</td><td align="left">2.805</td><td align="left">11.953</td><td align="left">5.977</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.172</td></tr><tr><td align="left"><bold>12</bold></td><td align="left">&#x02013;9.148</td><td align="left">2.805</td><td align="left">11.953</td><td align="left">5.977</td><td align="char" char=".">0.167</td><td align="left">&#x02013;3.172</td></tr><tr><td align="left"><bold>13</bold></td><td align="left">&#x02013;9.174</td><td align="left">1.771</td><td align="left">10.945</td><td align="left">5.473</td><td align="char" char=".">0.183</td><td align="left">&#x02013;3.702</td></tr><tr><td align="left"><bold>14</bold></td><td align="left">&#x02013;9.239</td><td align="left">1.781</td><td align="left">11.020</td><td align="left">5.510</td><td align="char" char=".">0.181</td><td align="left">&#x02013;3.729</td></tr><tr><td align="left"><bold>15</bold></td><td align="left">&#x02013;9.090</td><td align="left">1.735</td><td align="left">10.825</td><td align="left">5.413</td><td align="char" char=".">0.185</td><td align="left">&#x02013;3.677</td></tr></tbody></table></table-wrap></sec></sec><sec id="S0003-S2004" disp-level="2"><label>3.4.</label><title>Molecular docking results</title><p>Estimation of the feasible binding geometries and interactions between drugs and active site of proteins (Matin, Bhattacharjee, et al., <xref rid="CIT0028" ref-type="bibr">2019</xref>; Matin, Bhuiyan, et al., <xref rid="CIT0032" ref-type="bibr">2019</xref>) is obtained from molecular docking (Ghosh et al., <xref rid="CIT0011" ref-type="bibr">2020</xref>). Molecular docking score of esters <bold>4</bold>&#x02013;<bold>15</bold> along with standard antibiotic ampicillin (AMP) and hydroxychloroquine (HCQ) are shown in <xref rid="t0007" ref-type="table">Table 8</xref>. We calculated docking score (binding affinity) of <bold>13</bold>&#x02013;<bold>14</bold>, as these chlorobenzoyl compounds showed promising antifungal activities, with lanosterol 14&#x003b1;-demethylase (CYP51A1) and <italic>A. flavus</italic> (1R51) while all the uridine esters were considered for COVID-19 main protease (7BQY). In addition, other uridine esters <bold>4</bold>&#x02013;<bold>12</bold> expressed, in average, somewhat lower docking score than <bold>13</bold>&#x02013;<bold>14</bold> against CYP51A1 and 1R51.</p><table-wrap id="t0008" orientation="portrait" position="float"><label>Table 8.</label><caption><p>Molecular docking score of <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Drugs</th><th align="center">CYP51A1 (kcal/mol)</th><th align="center">1R51 (kcal/mol)</th><th align="center">7BQY (kcal/mol)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>4</bold></td><td align="center">&#x02013;8.8</td><td align="center">&#x02013;8.1</td><td align="center">&#x02013;7.7</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">&#x02013;9.0</td><td align="center">&#x02013;7.3</td><td align="center">&#x02013;7.9</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">&#x02013;8.5</td><td align="center">&#x02013;7.2</td><td align="center">&#x02013;6.6</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">&#x02013;7.5</td><td align="center">&#x02013;7.5</td><td align="center">&#x02013;8.0</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">&#x02013;9.2</td><td align="center">&#x02013;6.4</td><td align="center">&#x02013;8.0</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">&#x02013;9.0</td><td align="center">&#x02013;6.0</td><td align="center">&#x02013;6.4</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">&#x02013;5.4</td><td align="center">&#x02013;5.8</td><td align="center">&#x02013;5.5</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">&#x02013;6.6</td><td align="center">&#x02013;6.3</td><td align="center">&#x02013;4.9</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">&#x02013;4.5</td><td align="center">&#x02013;5.8</td><td align="center">&#x02013;5.2</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">&#x02013;12.0</td><td align="center">&#x02013;9.3</td><td align="center">&#x02013;7.7</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">&#x02013;11.1</td><td align="center">&#x02013;7.7</td><td align="center">&#x02013;7.6</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">&#x02013;8.3</td><td align="center">&#x02013;8.0</td><td align="center">&#x02013;7.8</td></tr><tr><td align="left"><bold>AMP</bold></td><td align="center">&#x02013;7.9</td><td align="center">&#x02013;7.5</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>HCQ</bold></td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;6.1</td></tr></tbody></table></table-wrap><p>Ampicillin (AMP) and HCQ were used as standard drugs; Discovery Studio (version 4.1) was performed for analysis and view of docking results.</p><p>Docking score clearly indicated that chlorobenzoyl esters <bold>13</bold>&#x02013;<bold>15</bold> had binding energy with both the CYP51A1 (&#x02013;7.9 to &#x02013;12.0&#x02009;kcal/mol; <xref ref-type="fig" rid="F0007">Figure 7(a,b)</xref>) and 1R51 (&#x02013;7.5 to &#x02013;9.3&#x02009;kcal/mol; <xref ref-type="fig" rid="F0007">Figure 7(c,d)</xref>) proteins which were higher than the standard antibiotic ampicillin (&#x02013;7.9 and &#x02013;7.5&#x02009;kcal/mol). The results are in complete accord with the <italic>in vitro</italic> results (<xref rid="t0004" ref-type="table">Table 5</xref>) that these uridine esters had better antifungal activities.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>(a) Docking pose (represented in space-filling model) of <bold>13</bold>, <bold>14</bold> and ampicillin with CYP51A1; (b) 2D interaction map of <bold>13</bold>, <bold>14</bold> and ampicillin with CYP51A1; (c) Docking pose of <bold>14</bold>, <bold>15</bold> and ampicillin with 1R51; (d) 2D interaction map of <bold>14</bold>, <bold>15</bold> and ampicillin with 1R51.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0007_C"/></fig><p>Considering the current COVID-19 pandemic caused by the SARS-CoV-2 betacoronavirus (Ghosh et al., <xref rid="CIT0011" ref-type="bibr">2020</xref>; Lakshmi et al., <xref rid="CIT0021" ref-type="bibr">2020</xref>) we have extended our studies by docking with COVID-19 main protease (7BQY). As shown in <xref rid="t0007" ref-type="table">Table 8</xref>, most of the uridine esters showed higher binding affinity with 7BQY than HCQ (&#x02013;6.1&#x02009;Kcal/mol). It is worth to mention that saturated fatty acyl esters with <bold>5</bold>, <bold>7</bold>&#x02013;<bold>8</bold> smaller chain length exhibited better binding affinity than the higher chain length <bold>9</bold>&#x02013;<bold>12</bold>, sulphonyl ester <bold>6</bold> and chlorobenzoyl esters <bold>13</bold>&#x02013;<bold>15</bold> (<xref ref-type="fig" rid="F0008">Figure 8</xref>). The docking score of <bold>5</bold>, <bold>7</bold> and <bold>8</bold> (&#x02013;7.9 to &#x02013;8.0&#x02009;kcal/mol) were found to better than the previously published other compounds (Ghosh et al., <xref rid="CIT0011" ref-type="bibr">2020</xref>). Thus, uridine aliphatic esters could be better choice than HCQ in treating COVID-19 infection.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>(a) Docked pose (represented in space-filling model) and (b) 2D interaction map of <bold>13</bold>, <bold>14, 15</bold> and HCQ with 7BQY.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0008_C"/></fig></sec><sec id="S0003-S2005" disp-level="2"><label>3.5.</label><title>Cytotoxic activity of the uridine esters 4&#x02013;15</title><p>The toxicity activity of the acylated uridine derivatives <bold>4</bold>&#x02013;<bold>15</bold> in the brine shrimp lethality bioassay method (McLaughlin, <xref rid="CIT0038" ref-type="bibr">1991</xref>) is presented in <xref ref-type="fig" rid="F0009">Figure 9</xref>, which showed the percentage of mortality of shrimps at 24&#x02009;h and 48&#x02009;h. From the data, it was evident that the test chemicals 5&#x02032;&#x002d7;<italic>O</italic>&#x002d7;(4&#x002d7;<italic>t&#x002d7;</italic>butylbenzoyl)&#x002d7;2&#x02032;,3&#x02032;&#x002d7;di&#x002d7;<italic>O</italic>&#x002d7;pentanoyl-uridine (<bold>7</bold>) and 5&#x02032;-<italic>O</italic>-(4-<italic>t</italic>-butylbenzoyl)-2&#x02032;,3&#x02032;-di-<italic>O</italic>-lauroyluridine (<bold>10</bold>) showed highest levels of toxicity (i.e. &#x0223c;57% death) indicating its higher mortality. The rest of the compounds were found less toxic for brine shrimp (<xref ref-type="fig" rid="F0009">Figure 9</xref>).</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>Cytotoxic activity of the uridine esters <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1850358_F0009_C"/></fig></sec><sec id="S0003-S2006" disp-level="2"><label>3.6.</label><title>ADME/T properties</title><p>Absorption, distribution, metabolism, excretion and toxicity (ADMET) related pharmacokinetic profile is mentioned in <xref rid="t0008" ref-type="table">Table 9</xref>. It is evident that these compounds possess better absorption value than standard antibiotics (ampicillin and nystatin) although they are P-glycoprotein inhibitor (except <bold>15</bold>). Distribution like BBB (&#x0003e;&#x02013;1) and CNS (&#x0003e;&#x02013;2) permeability values are comparable to standard drugs. Compounds <bold>4</bold>&#x02013;<bold>14</bold> are CYP3A4 enzyme substrate while <bold>15</bold> is non-substrate for this enzyme. Their excretion, presented as total clearance, is comparable to ampicillin.</p><table-wrap id="t0009" orientation="portrait" position="float"><label>Table 9.</label><caption><p>ADMET calculation of uridine derived esters <bold>4</bold>&#x02013;<bold>15</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="3" align="left">Drug</th><th colspan="3" align="center">Absorption<hr/></th><th colspan="2" align="center">Distribution<hr/></th><th align="center">Metabolism</th><th align="center">Excretion</th><th colspan="2" align="center">Toxicity<hr/></th></tr><tr><th rowspan="2" align="center">C2P</th><th rowspan="2" align="center">HIA<break/>(%)</th><th rowspan="2" align="center">P-gpI</th><th align="center">BBB</th><th align="center">CNS</th><th rowspan="2" align="center">CYP3A4 substrate</th><th rowspan="2" align="center">Total clearance</th><th rowspan="2" align="center">hERG<break/>inhibitor</th><th rowspan="2" align="center">Acute<break/>LD50</th></tr><tr><th colspan="2" align="center">(permeability)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">&#x02013;0.149</td><td align="center">50.745</td><td align="center">No</td><td align="center">&#x02013;1.401</td><td align="center">&#x02013;4.44</td><td align="center">No</td><td align="center">0.662</td><td align="center">No</td><td align="center">2.032</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">0.849</td><td align="center">64.746</td><td align="center">Yes</td><td align="center">&#x02013;1.269</td><td align="center">&#x02013;3.577</td><td align="center">Yes</td><td align="center">1.05</td><td align="center">No</td><td align="center">2.156</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">&#x02013;0.307</td><td align="center">73.091</td><td align="center">Yes</td><td align="center">&#x02013;1.516</td><td align="center">&#x02013;3.533</td><td align="center">Yes</td><td align="center">0.675</td><td align="center">No</td><td align="center">1.94</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">&#x02013;0.356</td><td align="center">64.449</td><td align="center">Yes</td><td align="center">&#x02013;2.322</td><td align="center">&#x02013;4.004</td><td align="center">Yes</td><td align="center">0.519</td><td align="center">No</td><td align="center">2.068</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">&#x02013;0.386</td><td align="center">80.936</td><td align="center">Yes</td><td align="center">&#x02013;1.038</td><td align="center">&#x02013;3.206</td><td align="center">Yes</td><td align="center">0.79</td><td align="center">No</td><td align="center">2.379</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">&#x02013;0.431</td><td align="center">76.614</td><td align="center">Yes</td><td align="center">&#x02013;1.042</td><td align="center">&#x02013;3.11</td><td align="center">Yes</td><td align="center">0.822</td><td align="center">No</td><td align="center">2.588</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">&#x02013;0.654</td><td align="center">82.458</td><td align="center">Yes</td><td align="center">&#x02013;1.081</td><td align="center">&#x02013;2.883</td><td align="center">Yes</td><td align="center">0.943</td><td align="center">No</td><td align="center">2.866</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">&#x02013;0.764</td><td align="center">85.355</td><td align="center">Yes</td><td align="center">&#x02013;1.099</td><td align="center">&#x02013;2.836</td><td align="center">Yes</td><td align="center">0.855</td><td align="center">No</td><td align="center">2.769</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">&#x02013;0.874</td><td align="center">88.256</td><td align="center">Yes</td><td align="center">&#x02013;1.117</td><td align="center">&#x02013;2.79</td><td align="center">Yes</td><td align="center">0.913</td><td align="center">No</td><td align="center">2.645</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">&#x02013;0.984</td><td align="center">91.157</td><td align="center">Yes</td><td align="center">&#x02013;1.136</td><td align="center">&#x02013;2.743</td><td align="center">Yes</td><td align="center">0.972</td><td align="center">No</td><td align="center">2.543</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">&#x02013;0.311</td><td align="center">97.276</td><td align="center">Yes</td><td align="center">&#x02013;1.155</td><td align="center">&#x02013;2.956</td><td align="center">Yes</td><td align="center">0.377</td><td align="center">No</td><td align="center">2.317</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">&#x02013;0.213</td><td align="center">97.221</td><td align="center">Yes</td><td align="center">&#x02013;1.188</td><td align="center">&#x02013;2.936</td><td align="center">Yes</td><td align="center">0.503</td><td align="center">No</td><td align="center">2.315</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">&#x02013;0.276</td><td align="center">100</td><td align="center">No</td><td align="center">&#x02013;1.554</td><td align="center">&#x02013;2.846</td><td align="center">No</td><td align="center">0.026</td><td align="center">No</td><td align="center">2.284</td></tr><tr><td align="left"><bold>AMP</bold></td><td align="center">0.395</td><td align="center">43.034</td><td align="center">No</td><td align="center">&#x02013;0.767</td><td align="center">&#x02013;3.166</td><td align="center">No</td><td align="center">0.337</td><td align="center">No</td><td align="center">1.637</td></tr><tr><td align="left"><bold>NYS</bold></td><td align="center">&#x02013;0.609</td><td align="center">0.00</td><td align="center">No</td><td align="center">&#x02013;2.09</td><td align="center">&#x02013;3.702</td><td align="center">No</td><td align="center">&#x02013;1.357</td><td align="center">No</td><td align="center">2.518</td></tr></tbody></table><table-wrap-foot><fn id="TF14"><p>C2P: Caco-2 permeability (log Papp in 10<sup>-6&#x02009;</sup>cm/s, &#x0003e;0.90 indicates high permeability); HIA: Human intestinal absorption (% absorbed, &#x0003e;30% is better absorbed); P-gpI: P-glycoprotein inhibitor; BBB (blood brain barrier) is expressed in logBB (logBB &#x0003e;-1.0 is moderately cross blood brain barrier); CNS (central nervous system) is expressed as logPS (logPS &#x0003e; &#x02013;2.0 can easily penetrate the CNS); Total clearance is expressed in log mL/min/kg; hERG: human ether-&#x000e0;-go-go-related gene I; Toxicity is calculated in oral rat acute toxicity (mol/kg); AMP: ampicillin; NYS: nystatin.</p></fn></table-wrap-foot></table-wrap><p>We have also calculated their toxicity values along with standard antibiotics. hERG (human ether&#x02010;&#x000e0;&#x02010;go&#x02010;go&#x02010;related gene I) showed negative values for these compounds like nystatin. Hence, these compounds could be safe and will not generate QT syndrome like fatal ventricular arrhythmia (Matin, Bhattacharjee, et al., <xref rid="CIT0028" ref-type="bibr">2019</xref>; Matin, Bhuiyan, et al., <xref rid="CIT0032" ref-type="bibr">2019</xref>; Matin, Chakraborty, et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>). In addition, it is important to consider the lethal dosage (LD<sub>50</sub>) values and is used to assess the relative toxicity of different molecules. Here, most of the ester's LD<sub>50</sub> values (&#x0003c;3&#x02009;mol/kg) are in good consistent with the value of nystatin (2.52&#x02009;mol/kg).</p><p>Drug likeness calculations were calculated from SwissADME tool and are summarized in <xref rid="t0009" ref-type="table">Table 10</xref>. For comparison both the uridine esters and standard antibiotics' drug likeness values were calculated. It was found that all the esters (except mesylate <bold>6</bold>) have good hydrogen bonds donor and acceptor which is in consistent with the Lipnski's rule of five. The more the value topological polar surface area (TPSA) more the polarity of the compounds and should be less than 140 &#x000c5;<sup>2</sup>. The TPSA in these molecules was in excellent agreement (&#x0223c;143 &#x000c5;<sup>2</sup>) with the most important rules of drug likeness (Lipinski et al., <xref rid="CIT0024" ref-type="bibr">1997</xref>).</p><table-wrap id="t0010" orientation="portrait" position="float"><label>Table 10.</label><caption><p>Calculation drug likeness using SwissADME.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Drug</th><th align="center">HB acceptors</th><th align="center">HB donors</th><th align="center">TPSA<break/>&#x000c5;&#x000b2;</th><th align="center">CYP1A2 inhibitor</th><th align="center">CYP2C19 inhibitor</th><th align="center">CYP2C9 inhibitor</th><th align="center">CYP2D6 inhibitor</th><th align="center">CYP3A4 inhibitor</th><th align="center">PAINS alerts</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">6</td><td align="center">4</td><td align="center">124.78</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>4</bold></td><td align="center">7</td><td align="center">3</td><td align="center">130.85</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">0</td></tr><tr><td align="left"><bold>6</bold></td><td align="center">11</td><td align="center">1</td><td align="center">193.89</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">0</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">0</td></tr><tr><td align="left"><bold>8</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">0</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>12</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>15</bold></td><td align="center">9</td><td align="center">1</td><td align="center">142.99</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>AMP</bold></td><td align="center">5</td><td align="center">3</td><td align="center">138.03</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr><tr><td align="left"><bold>NYS</bold></td><td align="center">18</td><td align="center">12</td><td align="center">319.61</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">0</td></tr></tbody></table><table-wrap-foot><fn id="TF15"><p>*HB: hydrogen bond; TPSA: topological polar surface area, PAINS: Pan-assay interference compounds, AMP: ampicillin, NYS: nystatin.</p></fn></table-wrap-foot></table-wrap><p>In the present study, we have checked the CYP enzymes, particularly isoforms 1A2, 2C9, 2C19, 2D6 and 3A4, inhibitory activities which are responsible for about 90% oxidative metabolic reactions. Inhibition of CYP enzymes will lead to inductive or inhibitory failure of drug metabolism. These inhibitions of compound <bold>4</bold>, <bold>9</bold>&#x02013;<bold>12</bold> and <bold>15</bold> were found similar to that of the standard drugs (<xref rid="t0009" ref-type="table">Table 10</xref>). In addition, Pan-assay interference compounds (PAINS) revealed no violation with these uridine esters. PAINS are chemical compounds that often give false positive results in high-throughput screens. PAINS tend to react nonspecifically with numerous biological targets rather than specifically affecting one desired target. Many studies indicated the acute toxic effects of medicines on non-targeted organisms, and hence, the MTT, MTS and Resazurin assay methods are used to check the cytotoxic concentration of any new molecule (synthetic or natural) which gives an idea about the maximum nontoxic dose of the drug molecule. We hope to conduct such studies for the more drug related validation of these promising uridine compounds.</p></sec><sec id="S0003-S2007" disp-level="2"><label>3.7.</label><title>Structure&#x02013;activity relationship</title><p>It was observed that the most of the potential antifungal drugs (fluconazole; itraconazole; voriconazole; terbinafine) are designed to deter the activity of CYP51A1 enzyme to synthesize essential ergosterol (Matin, Chakraborty, et al., <xref rid="CIT0033" ref-type="bibr">2020</xref>; Matin, Hasan, et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>; Matin, Roshid, et al., <xref rid="CIT0037" ref-type="bibr">2020</xref>). On the basis of our study, it could be thought that the effective uridine esters <bold>13</bold>&#x02013;<bold>15</bold> restricted CYP51 enzyme activity by binding with it, and hence, fungal ergosterol could not form. The unavailability of ergosterol ultimately causes disruption of the fungal cell wall causing organisms death.</p><p>On the other hand, saturated fatty acyl esters with <bold>5</bold>, <bold>7</bold>&#x02013;<bold>8</bold> smaller chain length (C2&#x02013;C6) showed slightly better binding score (&#x02013;7.9 to &#x02013;8.0&#x02009;kcal/mol) than chlorobenzoyl esters <bold>13</bold>&#x02013;<bold>15</bold> (&#x02013;7.6 to &#x02013;7.8&#x02009;kcal/mol) with 7BQY (COVID-19 main protease). Methanesuphonyl ester <bold>6</bold> (&#x02013;6.6&#x02009;kcal/mol) and HQC (&#x02013;6.1&#x02009;kcal/mol) had lower binding energy. The present results, thus, might have pave the way for discovery of novel drugs related to COVID-19 treatment although related further study is needed.</p></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusion</title><p>Covid-19, toxicity and evolution of MDR organisms in the microbial world caused a huge threat, and hence, novel antiviral and antimicrobial drugs preferably with newer mode of action, and reduced side-effects are essential. In this context several uridine esters were analyzed <italic>in vitro</italic> and <italic>in silico</italic> for their antimicrobial, thermodynamic, molecular docking and drug likeness properties. The study revealed that chloro-substituted benzoyl esters <bold>13</bold>&#x02013;<bold>15</bold> of uridine were more potential against fungal organisms with better pharmacokinetic and drug likeness spectra. In addition, some aliphatic acyl esters especially with lower carbon chains (C2-C6) showed promising binding score with COVID-19 main protease (7BQY). In this promising context, more drug likeness <italic>in vitro</italic> and <italic>in vivo</italic> study such as nontoxic concentration towards healthy cells may be conducted in the near future.</p></sec></body><back><ack><title>Acknowledgements</title><p>S. A. Chowdhury would like to thank Ministry of Science and Technology, Bangladesh for PhD fellowship. The authors are grateful to the Institute of Marine Science, University of Chittagong, Bangladesh and the Department of Physiology, Biochemistry &#x00026; Pharmacology, University of Chittagong Veterinary and Animal Science, Bangladesh for providing facilities during cytotoxic and antimicrobial evaluation.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awual</surname><given-names>M. R.</given-names></name></person-group> (<year>2017</year>). <article-title>New type mesoporous conjugate material for selective optical copper(II) ions monitoring &#x00026; removal from polluted waters</article-title>. <source><italic toggle="yes">Chemical Engineering Journal</italic></source>, , <fpage>85</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.cej.2016.07.110</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banasch</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Goetze</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Knyhala</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Potthoff</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Schlottmann</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kwiatek</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Bulut</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Schmitz</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>W. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Brockmeyer</surname><given-names>N. H.</given-names></name></person-group> (<year>2006</year>). <article-title>Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients</article-title>. <source><italic toggle="yes">AIDS (London, England)</italic></source>, (<issue>11</issue>), <fpage>1554</fpage>&#x02013;<lpage>1556</lpage>. <pub-id pub-id-type="doi">10.1097/01.aids.0000237373.38939.14</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlezon</surname><given-names>W. A.</given-names><suffix>Jr.</suffix></name>, <name name-style="western"><surname>Mague</surname><given-names>S. D.</given-names></name>, <name name-style="western"><surname>Parow</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Stoll</surname><given-names>A. L.</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>B. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Renshaw</surname><given-names>P. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats</article-title>. <source><italic toggle="yes">Biological Psychiatry</italic></source>, (<issue>4</issue>), <fpage>343</fpage>&#x02013;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2004.11.038</pub-id><pub-id pub-id-type="pmid">15705349</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. R.</given-names></name>, <name name-style="western"><surname>Ozeki</surname><given-names>Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Kawsar</surname><given-names>S. M. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Simple and rapid synthesis of some nucleoside derivatives: Structural and spectral characterization</article-title>. <source><italic toggle="yes">Current Chemistry Letters</italic></source>, (<issue>2</issue>), <fpage>83</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.5267/j.ccl.2015.12.001</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Clayden</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Greeves</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Wothers</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <source><italic toggle="yes">Organic chemistry</italic></source> (<edition>2nd ed.,</edition> p. <fpage>1234</fpage>). <publisher-name>Oxford University Press</publisher-name>.</mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>N.</given-names></name>, &#x00026; <name name-style="western"><surname>Benson</surname><given-names>S. W.</given-names></name></person-group> (<year>1993</year>). <article-title>Estimation of heats of formation of organic compounds by additivity methods</article-title>. <source><italic toggle="yes">Chemical Reviews</italic></source>, (<issue>7</issue>), <fpage>2419</fpage>&#x02013;<lpage>2438</lpage>. <pub-id pub-id-type="doi">10.1021/cr00023a005</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>A 40-year journey in search of selective antiviral chemotherapy</article-title>. <source><italic toggle="yes">Annual Review of Pharmacology and Toxicology</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010510-100228</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobolyi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Juh&#x000e1;sz</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Kov&#x000e1;cs</surname><given-names>Z.</given-names></name>, &#x00026; <name name-style="western"><surname>Kardos</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Uridine function in the central nervous system</article-title>. <source><italic toggle="yes">Current Topics in Medicinal Chemistry</italic></source>, (<issue>8</issue>), <fpage>1058</fpage>&#x02013;<lpage>1067</lpage>. <pub-id pub-id-type="doi">10.2174/156802611795347618</pub-id><pub-id pub-id-type="pmid">21401495</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.-H.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J.-H.</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>N.-N.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>B.-Z.</given-names></name>, <name name-style="western"><surname>Ou</surname><given-names>Z.-M.</given-names></name>, &#x00026; <name name-style="western"><surname>Luo</surname><given-names>X.-P.</given-names></name></person-group> (<year>2018</year>). <article-title>Enzymatic synthesis of nucleoside analogues from uridines and vinyl esters in a continuous-flow microreactor</article-title>. <source><italic toggle="yes">RSC Advances</italic></source>, (<issue>23</issue>), <fpage>12614</fpage>&#x02013;<lpage>12618</lpage>. <pub-id pub-id-type="doi">10.1039/c8ra01030g</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escober</surname><given-names>J. F. B.</given-names></name>, <name name-style="western"><surname>Carmona</surname><given-names>V. H. A.</given-names></name>, <name name-style="western"><surname>Jaramillo</surname><given-names>E. G.</given-names></name>, <name name-style="western"><surname>Margarita</surname><given-names>D. M. M.</given-names></name>, <name name-style="western"><surname>Fern&#x000e1;ndez</surname><given-names>M. E. M.</given-names></name>, <name name-style="western"><surname>Guerrero</surname><given-names>M. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Mart&#x000ed;nez</surname><given-names>A. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Synthesis and cytotoxic activity of tri-acyl ester derivatives of uridine in breast cancer cells</article-title>. <source><italic toggle="yes">Ars Pharmaceutica</italic></source>, (<issue>4</issue>), <fpage>183</fpage>&#x02013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.4321/S2340-98942016000400005</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Chakraborty</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Biswas</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Chowdhuri</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors &#x02013; an <italic>in silico</italic> docking and molecular dynamics simulation study</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1779818</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Anwar</surname><given-names>M. N.</given-names></name></person-group> (<year>2003</year>). <article-title>Comparative studies on selective acylation and antimicrobial activities of some D-glucofuranose derivatives</article-title>. <source><italic toggle="yes">Journal of Bangladesh Academy of Sciences</italic></source>, (<issue>1</issue>), <fpage>43</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>K. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Anwar</surname><given-names>M. N.</given-names></name></person-group> (<year>2002</year>). <article-title>Synthesis and antimicrobial activities of some acylated uridine derivatives</article-title>. <source><italic toggle="yes">Journal of the Bangladesh Chemical Society</italic></source>, (<issue>1</issue>), <fpage>13</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Kawsar</surname><given-names>S. M. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Selective acylation of uridine using the dibutyltin oxide and direct methods</article-title>. <source><italic toggle="yes">Chittagong University Studies, Part II: Science</italic></source>, (<issue>2</issue>), <fpage>39</fpage>&#x02013;<lpage>45</lpage>.</mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Kawsar</surname><given-names>S. M. A.</given-names></name></person-group> (<year>1998</year>). <article-title>Synthesis and antibacterial activities of some uridine derivatives</article-title>. <source><italic toggle="yes">The Chittagong University Journal of Science</italic></source>, (<issue>1</issue>), <fpage>13</fpage>&#x02013;<lpage>18</lpage>.</mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Kawsar</surname><given-names>S. M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Anwar</surname><given-names>M. N.</given-names></name></person-group> (<year>1998</year>). <article-title>Antibacterial activities of some selectively acylated uridine derivatives</article-title>. <source><italic toggle="yes">The Chittagong University Journal of Science</italic></source>, (<issue>2</issue>), <fpage>37</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Mridha</surname><given-names>M. A. U.</given-names></name>, &#x00026; <name name-style="western"><surname>Shahed</surname><given-names>S. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Antifungal activities of some methyl 6-<italic>O</italic>-trityl-&#x003b1;-D-mannopyranosides</article-title>. <source><italic toggle="yes">The Chittagong University Journal of Science</italic></source>, (<issue>1</issue>), <fpage>41</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Uddin</surname><given-names>M. R.</given-names></name></person-group> (<year>1998</year>a). <article-title>Comparative studies on selective acylation of uridine using the dibutyltin oxide and direct methods</article-title>. <source><italic toggle="yes">The Chittagong University Journal of Science</italic></source>, (<issue>1</issue>), <fpage>97</fpage>&#x02013;<lpage>103</lpage>.</mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>A. K. M. S.</given-names></name>, <name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Uddin</surname><given-names>M. R.</given-names></name></person-group> (<year>1998</year>b). <article-title>Selective myristoylation and palmitoylation of uridine</article-title>. <source><italic toggle="yes">The Chittagong University Journal of Science</italic></source>, (<issue>2</issue>), <fpage>27</fpage>&#x02013;<lpage>35</lpage>.</mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruse</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Goerigk</surname><given-names>L.</given-names></name>, &#x00026; <name name-style="western"><surname>Grimme</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Why the standard B3LYP/6-31G* model chemistry should not be used in DFT calculations of molecular thermochemistry: Understanding and correcting the problem</article-title>. <source><italic toggle="yes">The Journal of Organic Chemistry</italic></source>, (<issue>23</issue>), <fpage>10824</fpage>&#x02013;<lpage>10834</lpage>. <pub-id pub-id-type="doi">10.1021/jo302156p</pub-id><pub-id pub-id-type="pmid">23153035</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakshmi</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Shafreen</surname><given-names>R. M. B.</given-names></name>, <name name-style="western"><surname>Priya</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Shunmugiah</surname><given-names>K. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: Using structure-based drug discovery approach</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1778537</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laws</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Surani</surname><given-names>Y. M.</given-names></name>, <name name-style="western"><surname>Hasan</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Al-Adhami</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Chowdhury</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Imran</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Psaltis</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Jamshidi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Nahar</surname><given-names>K. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Rahman</surname><given-names>K. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Current trends and future approaches in small-molecule therapeutics for COVID-19</article-title>. <source><italic toggle="yes">Current Medicinal Chemistry</italic></source>, <pub-id pub-id-type="doi">10.2174/0929867327666200721161840</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lien</surname><given-names>E. J.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Z.-R.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>R.-L.</given-names></name>, &#x00026; <name name-style="western"><surname>Su</surname><given-names>C.-T.</given-names></name></person-group> (<year>1982</year>). <article-title>Use of dipole moment as a parameter in drug-receptor interaction and quantitative structure-activity relationship studies</article-title>. <source><italic toggle="yes">Journal of Pharmaceutical Sciences</italic></source>, (<issue>6</issue>), <fpage>641</fpage>&#x02013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1002/jps.2600710611</pub-id><pub-id pub-id-type="pmid">7097526</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Dominy</surname><given-names>B. W.</given-names></name>, &#x00026; <name name-style="western"><surname>Feeney</surname><given-names>P. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>. <source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source>, (<issue>1&#x02013;3</issue>), <fpage>3</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-409X</pub-id>(96)00423-1<pub-id pub-id-type="pmid">10837528</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucido</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Orlando</surname><given-names>B. J.</given-names></name>, <name name-style="western"><surname>Vecchio</surname><given-names>A. J.</given-names></name>, &#x00026; <name name-style="western"><surname>Malkowski</surname><given-names>M. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Crystal structure of aspirin-acetylated human cyclooxygenase-2: Insight into the formation of products with reversed stereochemistry</article-title>. <italic>Biochemistry</italic>, (<issue>8</issue>), <fpage>1226</fpage>&#x02013;<lpage>1238</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biochem.5b01378</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Synthesis of D-glucose derived oxetane: 1,2-<italic>O</italic>-isopropylidene-4-(<italic>S</italic>)-3-<italic>O</italic>,4-<italic>C</italic>-methylene-5-<italic>O</italic>-methanesulfonyl-&#x003b2;-L-threo-pento-1,4-furanose</article-title>. <source><italic toggle="yes">Journal of Applied Sciences Research</italic></source>, (<issue>11</issue>), <fpage>1478</fpage>&#x02013;<lpage>1482</lpage>.</mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Synthesis and antimicrobial study of some methyl 4-<italic>O</italic>-palmitoyl-&#x003b1;-L-rhamnopyranoside derivatives</article-title>. <source><italic toggle="yes">Orbital: The Electronic Journal of Chemistry</italic></source>, (<issue>1</issue>), <fpage>20</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.17807/orbital.v6i1.553</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Bhattacharjee</surname><given-names>S. C.</given-names></name>, <name name-style="western"><surname>Chakraborty</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Alam</surname><given-names>M. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Synthesis, PASS predication, in vitro antimicrobial evaluation and pharmacokinetic study of novel <italic>n</italic>-octyl glucopyranoside esters</article-title>. <source><italic toggle="yes">Carbohydrate Research</italic></source>, , <fpage>107812</fpage>
<pub-id pub-id-type="doi">10.1016/j.carres.2019.107812</pub-id><pub-id pub-id-type="pmid">31585251</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. H.</given-names></name>, <name name-style="western"><surname>Azad</surname><given-names>A. K. M. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Akther</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Design and synthesis of benzyl 4-<italic>O</italic>-lauroyl-&#x003b1;-L-rhamnopyranoside derivatives as antimicrobial agents</article-title>. <source><italic toggle="yes">Current Chemistry Letters</italic></source>, (<issue>1</issue>), <fpage>31</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.5267/j.ccl.2016.10.001</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. H.</given-names></name>, <name name-style="western"><surname>Debnath</surname><given-names>D. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Manchur</surname><given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Synthesis and comparative antimicrobial studies of some acylated D-glucofuranose and D-glucopyranose derivatives</article-title>. <source><italic toggle="yes">International Journal of Biosciences</italic></source>, (<issue>8</issue>), <fpage>279</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.12692/ijb/3.8.279-287</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. H.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Roshid</surname><given-names>M. H. O.</given-names></name></person-group> (<year>2015</year>). <article-title>Synthesis and comparative antibacterial studies of some benzylidene monosaccharide benzoates</article-title>. <source><italic toggle="yes">Journal of the Turkish Chemical Society, Section A: Chemistry</italic></source>, (<issue>4</issue>), <fpage>12</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.18596/jotcsa.83708</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. H.</given-names></name>, <name name-style="western"><surname>Kabir</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sanaullah</surname><given-names>A. F. M.</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Uzzaman</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Synthesis, characterization, ADMET, PASS predication, and antimicrobial study of 6-<italic>O</italic>-lauroyl mannopyranosides</article-title>. <source><italic toggle="yes">Journal of Molecular Structure</italic></source>, , <fpage>189</fpage>&#x02013;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2019.05.102</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Chakraborty</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Alam</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Hanee</surname><given-names>U.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel mannopyranoside esters as sterol 14&#x003b1;-demethylase inhibitors: Synthesis, PASS predication, molecular docking, and pharmacokinetic studies</article-title>. <source><italic toggle="yes">Carbohydrate Research</italic></source>, , <fpage>108130</fpage>
<pub-id pub-id-type="doi">10.1016/j.carres.2020.108130</pub-id><pub-id pub-id-type="pmid">32863019</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Hasan</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Uzzaman</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. H.</given-names></name>, <name name-style="western"><surname>Kibria</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Roshid</surname><given-names>M. H. O.</given-names></name></person-group> (<year>2020</year>). <article-title>Synthesis, spectroscopic characterization, molecular docking, and ADMET studies of mannopyranoside esters as antimicrobial agents</article-title>. <source><italic toggle="yes">Journal of Molecular Structure</italic></source>, , <fpage>128821</fpage>
<pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128821</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Ibrahim</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Synthesis of some methyl 4-<italic>O</italic>-octnoyl-&#x003b1;-L-rhamnopyranoside derivatives</article-title>. <source><italic toggle="yes">Journal of Applied Sciences Research</italic></source>, (<issue>10</issue>), <fpage>1527</fpage>&#x02013;<lpage>1532</lpage>.</mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Nath</surname><given-names>A. R.</given-names></name>, <name name-style="western"><surname>Saad</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname><given-names>M. M. H.</given-names></name>, <name name-style="western"><surname>Kadir</surname><given-names>F. A. A.</given-names></name>, <name name-style="western"><surname>Hamid</surname><given-names>S. B. A.</given-names></name>, <name name-style="western"><surname>Alhadi</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>M. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Yehye</surname><given-names>W. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Synthesis, PASS-predication and in vitro antimicrobial activity of benzyl 4-<italic>O</italic>-benzoyl-&#x003b1;-L-rhamnopyranoside derivatives</article-title>. <source><italic toggle="yes">International Journal of Molecular Sciences</italic></source>, (<issue>9</issue>), <fpage>1412</fpage>
<pub-id pub-id-type="doi">10.3390/ijms17091412</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Roshid</surname><given-names>M. H. O.</given-names></name>, <name name-style="western"><surname>Bhattacharjee</surname><given-names>S. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Azad</surname><given-names>A. K. M. S.</given-names></name></person-group> (<year>2020</year>). <article-title>PASS Predication, antiviral, <italic>in vitro</italic> antimicrobial, and ADMET studies of rhamnopyranoside esters</article-title>. <source><italic toggle="yes">Medical Research Archives</italic></source>, (<issue>7</issue>), <fpage>2165</fpage>
<pub-id pub-id-type="doi">10.18103/mra.v8i7.2165</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names>J. L.</given-names></name></person-group> (<year>1991</year>). Crown-gall tumours in potato discs and brine shrimp lethality: Two simple bioassays for higher plant screening and fractionation. In <person-group person-group-type="editor"><name name-style="western"><surname>Hostettmann</surname><given-names>K.</given-names></name></person-group> (Ed.), <source><italic toggle="yes">Methods in plant biochemistry: Assays for bioactivity</italic></source> (Vol. <volume>6</volume>, pp. 1-32). <publisher-name>Academic Press</publisher-name>.</mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>R. G.</given-names></name></person-group> (<year>1986</year>). <article-title>Absolute electronegativity and hardness correlated with molecular orbital theory</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source>, (<issue>22</issue>), <fpage>8440</fpage>&#x02013;<lpage>8441</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.83.22.8440</pub-id><pub-id pub-id-type="pmid">16578791</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>D. E. V.</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>T. L.</given-names></name>, &#x00026; <name name-style="western"><surname>Ascher</surname><given-names>D. B.</given-names></name></person-group> (<year>2015</year>). <article-title>pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures</article-title>. <source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source>, (<issue>9</issue>), <fpage>4066</fpage>&#x02013;<lpage>4072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id><pub-id pub-id-type="pmid">25860834</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharavanan</surname><given-names>V. J.</given-names></name>, <name name-style="western"><surname>Sivaramakrishnan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sivarajasekar</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Senthilrani</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kothandan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Dhakal</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Sivamani</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Show</surname><given-names>P. L.</given-names></name>, <name name-style="western"><surname>Awual</surname><given-names>M. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Naushad</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Pollutants inducing epigenetic changes and diseases</article-title>. <source><italic toggle="yes">Environmental Chemistry Letters</italic></source>, (<issue>2</issue>), <fpage>325</fpage>&#x02013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1007/s10311-019-00944-3</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>H. C.</given-names></name>, <name name-style="western"><surname>Doerffler</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Clarke</surname><given-names>M. O.</given-names></name>, <name name-style="western"><surname>Chun</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Neville</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Carra</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lew</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Wolfe</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Soloveva</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Knox</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Perron</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Stray</surname><given-names>K. M.</given-names></name>, <name name-style="western"><surname>Barauskas</surname><given-names>O.</given-names></name>, &#x02026; <name name-style="western"><surname>Mackman</surname><given-names>R. L.</given-names></name></person-group> (<year>2017</year>). <article-title>Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses</article-title>. <source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source>, (<issue>5</issue>), <fpage>1648</fpage>&#x02013;<lpage>1661</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01594</pub-id><pub-id pub-id-type="pmid">28124907</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strasser</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Maier</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Leisser</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Saiko</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Madlener</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bader</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Bernhaus</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Gueorguieva</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Richter</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mader</surname><given-names>R. M.</given-names></name>, <name name-style="western"><surname>Wesierska-Gadek</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Schott</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Szekeres</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Fritzer-Szekeres</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Krupitza</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2</article-title>. <source><italic toggle="yes">Differentiation; Research in Biological Diversity</italic></source>, (<issue>9&#x02013;10</issue>), <fpage>488</fpage>&#x02013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-0436.2006.00082.x</pub-id><pub-id pub-id-type="pmid">17177846</pub-id></mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Susilo</surname><given-names>R. (K&#x000f6;ln, DE).</given-names></name></person-group> (<year>2008</year>). Pharmaceutically active uridine esters, United States, Trommsdorff GmbH &#x00026; Co. KG Arzeneimittel (Alsdorf, DE) 7417034. <ext-link ext-link-type="uri" xlink:href="http://www.freepatentsonline.com/7417034.html">http://www.freepatentsonline.com/7417034.html</ext-link></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahedi</surname><given-names>H. M.</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Abbasi</surname><given-names>S. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Stilbene-based natural compounds as promising drug candidates against COVID-19</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1762743</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Koyama</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kurajoh</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shoji</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tsutsumi</surname><given-names>Z.</given-names></name>, &#x00026; <name name-style="western"><surname>Moriwaki</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Biochemistry of uridine in plasma</article-title>. <source><italic toggle="yes">Clinica Chimica Acta; International Journal of Clinical Chemistry</italic></source>, (<issue>19&#x02013;20</issue>), <fpage>1712</fpage>&#x02013;<lpage>1724</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2011.06.006</pub-id><pub-id pub-id-type="pmid">21689643</pub-id></mixed-citation></ref></ref-list></back></article>